Updated: 9 February 2018

**CURRICULUM VITAE**

**Name:** Glenville Jones

**Nationality:** British/Canadian Citizen

**Mailing Address:** Department of Biochemistry

6th Floor, Botterell Hall

Queen's University

Kingston, Ontario, Canada K7L 3N6

**EDUCATION**

B.Sc. Degree 1967, Liverpool University (Chemistry, General Biology)

B.Sc. (Honours) 1968, Liverpool University (Biochemistry)

Ph.D. Degree 1971, Liverpool University (Biochemistry), with Dr George A.J. Pitt

Postdoctoral Training University of Calgary, Alberta, Canada (With Dr. John N. Hawthorne)

(Oct. 1971-Oct. 1975) University of Wisconsin, Madison, U.S.A. (With Dr. Hector F. DeLuca)

**CURRENT POSITIONS HELD**

June 1 2011-Present Craine Professor of Biochemistry, Department of Biomedical & Molecular Sciences;

Professor, Department of Medicine, Queen’s University, Kingston, Ontario, Canada

July 2002-Present Scientific Advisory Board, Cytochroma/OPKO Renal, Miami, Florida, US

Sept 2017-Present Chair of Advisory Committee, Vitamin D External Quality Assurance Scheme (DEQAS)

**PAST POSITIONS HELD**

Nov. 1975 - Feb. 1984 Assistant Professor (1975-1982) & Associate Professor (1982-1984), Division of Endocrinology Research, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada

Assistant Professor (1975-1983) & Associate Professor (1983-1984), Depts. Biochemistry, Pediatrics & School of Graduate Studies, University of Toronto, Toronto, ON, Canada

Feb. 1984 - June 1988 Associate Professor, Depts of Medicine & Biochemistry, Queen's University, Kingston, ON,

July 1988 – June 2002 Professor of Biochemistry & Professor of Medicine, Queen's University, Kingston, ON Canada

July 1989 - July 1990 Visiting Professor, Department of Biochemistry, University of Arizona, Tucson, Arizona, U.S.A

Jan 1997 - Sept 2002 Co-founder, Vice-President & Chief Scientific Officer, Cytochroma Inc, Kingston, ON, Canada

July 2002- June 2011 Craine Professor of Biochemistry & Head, Department of Biochemistry

Professor, Department of Medicine, Queen’s University, Kingston, Ontario, Canada

May 2010-April 2013 Scientific Advisory Board, Receptor Inc, Toronto, Ontario, Canada

**AWARDS**

Feb 1984- Feb 1994 Medical Research Council Development Grant (10 year salary and equipment award)

April 2000 Queen’s University Biochemistry Student Teaching Award

September 2004 Career Research Excellence Award, 12th Annual Providence Symposium on Vitamin D, Providence, RI, USA

April 2006 Career Achievement Award, 13th International Workshop on Vitamin D, Victoria, Canada

July 2009 Outstanding Speaker Award 2009. Amer Assoc Clinical Chemistry, Chicago, IL, USA

July 2013 Research highlighted in CIHR-IMHA publication: *“Celebrating the Impact of Health Research: Success Stories in Arthritis, Bone, Muscle, Musculoskeletal Rehabilitation, Oral Health and Skin”.*

September 2014 Queen’s University 2014 Prize for Excellence in Research in Health Sciences

October 2015 European Vitamin D Association (EVIDAS) Award for Vitamin D Knowledge Translation

**NATIONAL & INTERNATIONAL SCIENTIFIC ACTIVITIES- HIGHLIGHTS**

1987-1991 Member, Fellowship Committee B, Medical Research Council.

1990-1994 Editorial Board, Journal of Bone & Mineral Research.

1991 Scientific Program Committee, 8th Workshop on Vitamin D, Paris, France.

1992-1996 Member, Metabolism & Nutrition Committee, Medical Research Council.

1994 Scientific Program Committee, 9th Workshop on Vitamin D, Orlando, FL USA.

1996-1997 Programme Grant Panelist, NIH-NCI, Bethesda, Maryland

1997-Present Scientific Advisory Board, Vitamin D External Quality Assurance Scheme (DEQAS)

1997 Scientific Program Committee, 10th Workshop on Vitamin D, Strasbourg, France.

1998 Delegate and member of working group, Joint FAO/WHO Panel for Dietary Intakes of Vitamins and Minerals that convened in Bangkok, Sept. 1998. Published as current worldwide guidelines in 2002.

1999-2000 Member, Metabolism & Nutrition Committee, Medical Research Council.

2000 Scientific Program Committee, 11th Workshop on Vitamin D, Nashville, TN, USA.

2001-2004 Programme Grant Panelist, NIH-NCI, Bethesda, Maryland

2001-2004 Invited Scientific Officer, Metabolism & Nutrition Grants Committee, CIHR

2001-2004 Inaugural Member, Institute Advisory Board, Canadian Institute of Nutrition, Metabolism & Diabetes.

2001-2004 Member, Metabolism & Nutrition Grants Committee, Canadian Institute of Health Research

2003 Scientific Program Committee, 12th Workshop on Vitamin D, Maastricht, Holland

2004-2006 Ontario Graduate Studentships, Selection Panel

2005-2006Scientific Program Committee, 13th Workshop on Vitamin D, Victoria, BC, Canada.

2006 Academic Review Committee, Biomedical, Biomolecular & Chemical Sci., U Western Australia, Perth, Australia.

2007-2010 Panel Member & Invited Scientific Officer, University/Industry Grants Committee, CIHR

2008-2009 Technical expert on Tufts University evidence-based report committee (AHRQ report) assessing “Relationships of Vitamin D and Calcium Intakes to Nutrient Status Indicators and Health Outcomes”

2008-2009Scientific Program Committee, 14th Workshop on Vitamin D, Bruges, Belgium.

2009-2011 National Academy of Sciences, Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium (Joint US/Canadian committee to review DRIs for vitamin D and Calcium).

2009-Present Editorial Board, Dermato-Endocrinology (Landes Bioscience Journals)

2011-2012 Program Advisory Committee, 15th Workshop on Vitamin D, Houston, TX.

2012-2013 Member, Program Grants in Nutrition Committee, Canadian Institutes of Health Research

2012-2013 Program Advisory Committee, 16th Workshop on Vitamin D, San Francisco, CA.

2013 Technical Expert Panel, Rand Corporation Vitamin D and Calcium Update Evidence Review (AHRQ report)

2016 CIHR Project Grant Competition Reviewer

2016-2017 Program Advisory Committee, 20th Workshop on Vitamin D, Orlando, FL

**RESEARCH INSTITUTE & UNIVERSITY APPOINTMENTS**

1979-1983 Secretary & Chairman, Research Training Committee, Hospital for Sick Children Research Institute.

1982-1984 Safety Officer, Hospital for Sick Children Research Institute.

1984-1987 Advisory Research Committee, School of Graduate Studies.

1990-1994 Graduate Programme Coordinator, Department of Biochemistry

1991-1994 Chairman, Division 1, School of Graduate Studies.

1992-1998Chairman, Queen’s National Scholar Programme

1999-2002Councillor, Life Sciences Programme

2000-2002 Undergraduate Advisor, Department of Biochemistry

2000-2002Chair, Appointments, Promotions and Tenure Committee, Department of Biochemistry

2001-2002 Faculty of Arts and Science, Curriculum Committee

2002-2003 SEAMO (South Eastern Ontario Medical Organisation) Basic Science Representative

2009 Chair, Internal Academic Review, Department of Chemistry, Queen’s University

2009 Committee Member, Faculty of Health Sciences Dean’s Advisory Group on Restructuring (AGoR)

2005-2011 SEAMO (South Eastern Ontario Medical Organisation) Basic Science Representative

2006-2012 Board of Directors, PARTEQ (Queen’s University Commercialisation of Intellectual Property arm)

2012 Member, Headship Search Committee, Department of Biomedical & Molecular Sciences

**SOCIETIES**

Canadian Biochemical Society;

American Society for Bone and Mineral Research (inaugural member);

American Society for Nephrology;

American Association of Clinical Chemistry

**PUBLICATIONS**

1. Jones G, Schnoes HK, DeLuca HF (1975) Isolation and identification of 1,25-dihydroxyvitamin D2. Biochemistry **14**:1250-1256. PMID: 1078978

2. Jones G, DeLuca HF (1975) High pressure liquid chromatography: Separation of the metabolites of vitamin D2 and D3 on small-particle silica columns. J Lipid Res **16**:448-453. PMID: 172574

3. Jones G, Schnoes HK, DeLuca HF (1976) An in vitro study of vitamin D2 hydroxylases in the chick. J Biol Chem **251**:24-28. PMID: 1081537

4. Jones G, Baxter L, DeLuca HF, Schnoes HK (1976) The biological activity of 1,25-dihydroxyvitamin D2 in the chick. Biochemistry **15**:713-716.

5. Lorenc R, Tanaka Y, DeLuca HF, Jones G (1977) Lack of effect of calcitonin on the regulation of vitamin D metabolism in the rat. Endocrinology **100**:468-472. PMID: 832634

6. Jones G (1977) Application of high pressure liquid chromatography for assay of vitamin D metabolites. In "Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism". Eds. Norman AW, et al., de Gruyter, New York, pp. 491-500.

7. Jones G (1978) Assay of vitamin D2 and D3, 25-hydroxyvitamins D2 and D3 in human plasma by high pressure liquid chromatography. Clin Chem **24**:287-298. PMID: 203413

8. Vieth R, Fraser D, Jones G (1978) A modified photography tank for continuous development of thin-layer chromatographic plates. Anal Chem **50**:2150-2152.

9. Jones G, Rosenthal A, Segev D, Mazur Y, Frolow F, Halfon Y, Rabinovich D, Shakked Z (1979) 24(R),25-dihydroxyvitamin D2 synthesis, determination of absolute configuration by X-ray analysis and identification as a kidney metabolite of vitamin D2. Tetrahedron Lett **2**:177-180.

10. Hay AWM, Jones G (1979) The elution profile of vitamin D2 metabolites from Sephadex LH-20 columns. Clin Chem **25**:473-475. PMID: 318054

11. Jones G, Rosenthal A, Segev D, Mazur Y, Frolow F, Halfon Y, Rabinovich D, Shakked Z (1979) Isolation and identification of 24,25-dihydroxyvitamin D2 using the perfused rat kidney. Biochemistry **18**:1094-1101. PMID: 311655

12. Kooh SW, Jones G, Reilly BJ, Fraser D (1979) Pathogenesis of rickets in hepatobiliary disease in children. J Pediatr **94**:870-874. PMID: 448526

13. Jones G, Byrnes B, Jeejeebhoy KN (1979) Contribution of skin vitamin D3 synthesis in patients receiving total parenteral nutrition. In "Vitamin D: Basic Research and its Clinical Application". Eds. Norman AW et al.; De Gruyter, Berlin, pp. 169-172.

14. Murray, T.M., Cifuentes, R.F., Jones, G. and Radde, I.C. (1979) Effects of graded doses of vitamin D3 on intestinal Ca transport, CaBP and CaATPase in the young pigs. In "Vitamin D: Basic Research and its Clinical Application". Eds. Norman AW et al.; De Gruyter, Berlin, pp. 655-658.

15. Rosenthal AM, Jones G, Fraser D, Kooh SW (1979) 1,25-(OH)2vitamin D3 and 24,25-(OH)2vitamin D3 synthesis by the isolated perfused rat kidney. In "Vitamin D: Basic Research and its Clinical Application". Eds. Norman AW et al.; De Gruyter, Berlin, pp. 613-616.

16. Jones G, Byrnes B, Palma F, Segev D, Mazur Y (1980) Displacement potency of vitamin D2 analogs in competitive protein-binding assays for 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3 and 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab **50**:773-775. PMID: 6965943

17. Shike M, Harrison JE, Sturtridge WC, Tam CS, Bobechko PE, Jones G, Murray TM, Jeejeebhoy KN (1980) Metabolic bone disease in patients receiving long-term total parenteral nutrition. Ann Intern Med **92**:343-350. PMID: 6766694

18. Rosenthal AM, Jones G, Kooh SW, Fraser D (1980) 25-Hydroxyvitamin D3 metabolism by the isolated perfused rat kidney. Am J Physiol (Endocrinol Metab 2) **239**:E12-E20. PMID: 6249124

19. Tam CS, Harrison JE, Heersche JNM, Jones G, Wilson DR, Parsons JA, Murray TM (1980) Short term variation in the rate of apposition of mineralized bone matrix in small animals. Metab Bone Dis et Rel Res **2**(S):159-166.

20. Jones G, Schnoes, HK, Levan L, DeLuca HF (1980) Isolation and identification of 24-hydroxyvitamin D2 and 24,25-dihydroxyvitamin D2. Arch Biochem Biophys **202**:450-457. PMID: 6970013

21. Jones G (1980) Ternary solvent mixtures for improved resolution of hydroxylated metabolites of Vitamin D2 and Vitamin D3 during high-performance liquid chromatography. J Chromatogr Biomed Appls **221**:27-37.

22. Tam CS, Jones G, Heersche JNM (1981) The effect of vitamin D restriction and repletion on bone apposition in the rat and its dependence on parathyroid hormone. Endocrinology **109**:1448-1453. PMID: 6271531

23. Gray TK, McAdoo T, Pool D, Lester GE, Williams ME, Jones G (1981) A modified radio-immunoassay for 1,25-dihydroxycholecalciferol. Clin Chem **27**:458-462. PMID: 6894110

24. Shike M, Sturtridge WC, Tam CS, Harrison JE, Jones G, Murray TM, Husdan H, Whitwell J, Wilson DR, Jeejeebhoy KN (1981) A possible role of vitamin D in the genesis of parenteral-nutrition-induced metabolic bone disease. Ann Int Med **95**:560-568. PMID: 6794407

25. Heersche JNM, Tam CS, Jones G (1981) Measurement of the apposition rate of mineralized bone matrix and osteoid in normal, D-restricted and D-repleted rats using simultaneous labelling with 3H proline and tetracycline. "Chemistry & Biology of Mineralized Connective Tissue". Ed. Veis A; Elsevier North-Holland Inc., Amsterdam, New York, pp. 313-315.

26. Jones G, Wong T-Y, Reddy GS, DeLuca HF (1982) Lack of 24-hydroxylation of 24,24-difluoro-25-hydroxyvitamin D3 in the perfused rat kidney. In "Vitamin D: Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism". Eds. Norman AW, Schaefer K, von Herrath D, Grigoleit, H-G;

De Gruyter, New York, pp. 191-193.

27. Atkinson SA, Jones G, Radde IC, Sheepers J (1982) Plasma 1,25-dihydroxyvitamin D3 (1,25diOHD), ionic and total calcium after oral doses of 1,25-diOHD and Ca-feeds in young piglets. In "Vitamin D: Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism". Eds. Eds. Norman AW, Schaefer K, von Herrath D, Grigoleit, H-G; De Gruyter, New York, pp. 579-581.

28. Mazur Y, Segev D, Jones G (1982) Synthesis and determination of absolute configuration of kidney metabolites of vitamin D. In "Vitamin D: Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism". Eds. Eds. Norman AW, Schaefer K, von Herrath D, Grigoleit, H-G; De Gruyter, New York, pp. 1101-1106.

29. Reddy GS, Norman AW, Mayer E, Jones G, Ho M, Tsang RC (1982) 25-Hydroxyvitamin D3-26,23-lactone synthesis by the isolated perfused rat kidney. In "Vitamin D: Chemical, Biochemical & Clinical Endocrinology of Calcium Metabolism". Eds. Norman AW et al.; De Gruyter, New York, pp. 511-513.

30. Reddy GS, Jones G, Kooh SW, Fraser D (1982) Inhibition of 25-hydroxyvitamin D3-1-hydroxylase by chronic metabolic acidosis: A study with the isolated perfused rat kidney. Amer J Physiol **243**: E265-E271. PMID: 7124941

31. Harrison JE, Hitchman AJW, Jones G, Tam CS, Heersche JNM (1982) Plasma vitamin D metabolite levels in phosphorus deficient rats during the development of vitamin D deficient rickets. Metabolism **31**:1121-1127. PMID: 7132739

32. Barnett BJ, Jones G, Cho CY, Slinger SJ (1982) The biological activity of 25-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol for rainbow trout (Salmo gairdneri). J Nutr **112**:2020-2026. PMID: 6290625

33. Jeejeebhoy KN, Shike M, Sturtridge WC, Tam CS, Jones G, Murray TM, Harrison JE (1982) TPN bone disease at Toronto. Metabolic bone disease in total parenteral nutrition. Presented in Chicago, IL, June 10, 1982.

34. Gillis J, Jones G, Pencharz P (1983) Delivery of vitamins A, D and E in total parenteral nutrition solutions.

JPEN J Parenteral Enteral Nutr **7**:11-14. PMID: 7132739

35. Jones G (1983) Chromatographic separation of 24(R),25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3-26,23-Lactone using a cyano-bonded phase packing. J Chromatogr Biomed Appl **276**:69-75. PMID: 6608527

36. Fraher LJ, Adami S, Clemens TL, Jones G, O'Riordan JLH (1983) Radioimmunoassay of 1,25-dihydroxyvitamin D2: Studies on the metabolism of vitamin D2 in man. Clin Endocrinol **18**:151-165. PMID: 6603929

37. Reddy GS, Jones G, Kooh SW, Fraser D, DeLuca HF (1983) Effects of metabolites and analogs of vitamin D3 on 24(R),25-dihydroxyvitamin D3 synthesis. Am J Physiol **245**:E359-E364. PMID: 6312806

38. Jones G, Kung M, Kano K (1983) The isolation and identification of two new metabolites of 25-hydroxyvitamin D3 produced in the kidney. J Biol Chem **258**:12920-12928. PMID: 6630213

39. Kano K, Jones G (1984) Direct in vitro effect of thyroid hormones on 25-hydroxyvitamin D3 metabolism in the perfused rat kidney. Endocrinology **114**:330-336. PMID: 6418528

40. Petkovich PM, Heersche JNM, Tinker DO, Jones G. (1984) Retinoic acid stimulates 1,25-(OH)2D3 binding in rat osteosarcoma cells. J Biol Chem **259**:8274-8280. PMID: 6330107

41. Jones G, Kano K, Yamada S, Furusawa T, Takayama H, Suda T (1984) Identification of 24,25,26,27-tetranor-23-(OH)D3 as a product of renal metabolism of 24,25-(OH)2D3. Biochemistry **23**:3749-3754. PMID: 6332645

42. Jones G, Seamark DA, Trafford DJH, Makin, HLJ (1985) Chapter 2: Vitamin D: Cholecalciferol Ergocalciferol and Hydroxylated Metabolites. In "Modern Chromatographic Analysis of the Vitamins". Chromatographic Science Series **30**  Eds. de Leenheer, AP, Lambert WE, de Ruyter M; Dekker M. New York & Basel, pp. 73-128.

43. Jones G (1985) Impact of microcomputers on vitamin D research. In "Vitamin D. Chemical, Biochemical and Clinical Update" Eds. Norman AW et al., De Gruyter Berlin and New York, pp. 155-163.

44. Lukaszkiewicz J, Lorenc R, Romer T, Garabedian M, Balsan S, Jones G. (1985) Growth Hormone induced catch-up growth and serum 1,25-(OH)2D concentrations in pituitary dwarfs. In: "Vitamin D. Chemical, Biochemical and Clinical Update" Eds. Norman AW et al. De Gruyter Berlin and New York, pp. 1109-1110.

45. Fraser D, Jones G, Koo SW, Radde IC (1985) Chapter 12: Calcium and phosphate metabolism. In "Clinical Chemistry", Ed. Tietz NW; WB Saunders, Philadelphia, pp. 1317-1372.

46. Yamada S, Ino E, Takayama H, Horiuchi N, Shinki T, Suda T, Jones G, DeLuca HF (1985) Differences in the side-chain metabolism of vitamin D3 between chicken and rats. Proc Natl Acad Sci USA **82**:7485-7489. PMID: 2999764

47. Harrison JE, Tam CS, Hitchman AJW, Hitchman A, Hasang SA, Jones G (1986) The relationship between bone appositional rate and vitamin D activity in phosphate deficient rats. Metabolism **35**:126-129. PMID: 3484801

48. Tam CS, Heersche JNM, Jones G, Murray TM, Rasmussen H (1986) The effect of vitamin D on bone apposition in vivo. Endocrinology **118**:2217-2224. PMID: 3486118

49. Jones G (1986) A new pathway of 25-hydroxyvitamin D3 metabolism. In: "Vitamins and Coenzymes”; Academic Press. Eds. McCormick DB, Chytil F. Methods in Enzymology **123**:141-154. PMID: 3702712

50. Jones G (1986) Chapter 9: "Fat-Soluble Vitamins. Part 1, Vitamin A and Vitamin D". In "Nutritional Aspects of Aging", Vol. 1, Ed. Chen L; CRC Press Inc., Boca Raton, pp. 195-212.

51. O'Leary TJ, Jones G, Yip A, Lohnes D, Cohanim M, Yendt ER (1986) The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med **315**:727-730. PMID: 3755800

52. Jones G (1986) Use of the perfused kidney and diode array spectrophotometry to study vitamin D metabolism. J Analysis & Purification **2**:12-19.

53. Fraser D, Jones G, Kooh SW, Radde IC (1987) Chapter 21: Calcium and Phosphate Metabolism. In "Fundamentals of Clinical Chemistry". Ed Tietz NW; W.B. Saunders, Philadelphia, pp. 705-728.

54. Petkovich PM, Heersche JNM, Aubin JE, Jones G(1987)Retinoic acid induced changes in 1,25-dihydroxyvitamin D3 receptor levels in tumor and non-tumor cells derived from rat bone. J Nat Cancer Inst **78**:265-270. PMID: 3027442

55. Tenenhouse HS, Jones G (1987) Effect of the X-linked Hyp Mutation and Vitamin D status on induction of renal 25-hydroxyvitamin D3-24-hydroxylase. Endocrinology **120**:609-616. PMID: 3803293

56. Jones G, Vriezen D, Lohnes D, Palda V, Edwards NS (1987) Side chain hydroxylation of vitamin D3 and its physiological implications. Steroids **49**:29-53. PMID: 2842896

57. Jones G, Yip A, Tenenhouse HS (1987) Side-chain oxidation of vitamin D3 in mouse kidney mitochondria: Effect of the Hyp mutation and 1,25-dihydroxyvitamin D3 treatment. Biochem Cell Biol **65**:853-859. PMID: 2833907

58. Lohnes D, Jones G (1987) Side-chain metabolism of vitamin D in osteosarcoma cell line UMR-106: Characterization of products. J Biol Chem **262**:14394-14401. PMID: 2822692

59. Tenenhouse HS, Yip A, Jones G (1988) Increased renal catabolism of 1,25-dihydroxyvitamin D3 in Murine X-linked hypophosphatemic rickets. J Clin Invest **81**:461-465. PMID: 3339128

60. Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA (1988) Effect of high dose budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am Rev Respir Dis **138**:57-61. PMID: 3202401

61. Jones G, Edwards N, Vriezen D, Porteous C, Trafford DJH, Cunningham J, Makin HLJ (1988) Isolation and identification of seven metabolites of 25-hydroxy-dihydrotachysterol3 formed in the isolated perfused rat kidney: A model for the study of side-chain metabolism of Vitamin D. Biochemistry **27**:7070-7079. PMID: 3196702

62. Lohnes D, Jones G (1988) Biosynthesis of water-soluble metabolites of 1,25-dihydroxyvitamin D3 by osteosarcoma UMR-106. In: "Vitamin D. Molecular, Cellular and Clinical Endocrinology" Eds. Norman AW et al.; de Gruyter, New York, pp 118-119.

63. Miller BE, Chin DP, Jones G (1988) 24-oxidation of 1,25-(OH)2D3 by a human osteosarcoma cell line, U-20S. In: "Vitamin D. Molecular, Cellular & Clinical Endocrinology" Eds. Norman AW et al.; de Gruyter, New York, pp 122-123.

64. Porteous C, Trafford DJH, Makin HLJ, Cunningham J, Jones G (1988) Use of mass spectrometry in the identification of in vivo and in vitro metabolites of dihydrotachysterol3 in the rat. Biomed Environ Mass Spectrom **16**:87-92. PMID: 3242712

65. Jones G, DeLuca HF (1988) High Performance Liquid Chromatography and its Application to Endocrinology. Monogr Endocrinol **30**:95-139. PMID: 3068529

66. Theodossiou M, Kung M, Jones G, Fraser D, Kooh, SW (1988) Effects of acute carbon tetrachloride poisoning on vitamin D3 metabolism in the rat. Can J Physiol Pharmacol **66**: 1542-1546. PMID: 2852538

67. Tam T, Strugnell S, Deeley R, Jones G (1988) 25-hydroxylation of vitamin D3 by human liver hepatoma cell lines in vitro. J Lipid Res **29**:1637-1642. PMID: 2854152

68. Phelps KR, Einhorn TA, Vigorita VJ, Jones G, Lundin AP (1989) Persistence of dialysis osteomalacia despite treatment with 24R,25-dihydroxycholecalciferol. Nephron **51**:197-206. PMID: 2783766

69. Kooh SW, Roberts EA, Fraser D, Curtis J, Jones G, Weber JL, Reilly BJ (1989) UV irradiation therapy for hepatobiliary rickets. Arch Dis Child **64**:617-619. PMID: 2546510

70. Makin G, Lohnes D, Byford V, Ray R, Jones G (1989) Target cell metabolism of 1,25-(OH)2D3 to calcitroic acid: evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J **262**:173-180. PMID: 2818561

71. Marx SJ, Jones G, Weinstein RS, Chrousos GP, Renquist DM (1989) Differences in Vitamin D and mineral metabolism among new world and old world primates. J Clin Endocrinol Metab **69**:1282-1290. PMID: 2555385

72. Cunningham J, Coldwell RD, Jones G, Tenenhouse HS, Trafford DJH, Makin HLJ (1990) Plasma 24,25-dihydroxyvitamin D3 concentrations in X-linked hypophosphatemic rickets: Studies using mass fragment-ographic and radioreceptor assays. J Bone Miner Res **5**:173-177. PMID: 2316405

73. Tomon M, Tenenhouse HS, Jones G (1990) 1,25-Dihydroxyvitamin D3-inducible catabolism of vitamin D metabolites in mouse intestine. G. Amer J Physiol **258**:G557-G563. PMID: 2159220

74. Romer TE, Lorenc RS, Lukaszkiewicz J, Garabedian M, Balsan S, Jones G (1990) Effects of growth hormone stimulated catch-up growth on serum 1,25-(OH)2D levels of growth hormone deficient patients. Endokrynolgia Polska **41**:271-279.

75. Tenenhouse HS, Jones G (1990) Abnormal Regulation of Renal Vitamin D Catabolism by Dietary Phosphate in Murine X-linked hypophosphatemic Rickets. J Clin Invest **85**:1450-1455. PMID: 2332500

76. Strugnell S, Calverley MJ, Jones G (1990) Metabolism of a cyclopropane-ring-containing analog of 1α-hydroxy vitamin D3 in a hepatocyte cell model: Identification of 24-oxidised metabolites. Biochem Pharmacol **40**:333-341. PMID: 2375769

77. Miller BE, Chin DP, Jones G (1990) 1,25-Dihydroxyvitamin D3 metabolism in a human osteosarcoma cell line and human bone cells. J Bone Mineral Res **5**:597-607. PMID: 2166423

78. Tomon M, Tenenhouse HS, Jones G. (1990) Expression of 25-hydroxyvitamin D3-24-hydroxylase activity in CaCo-2 cells. An In Vitro model of intestinal vitamin D catabolism. Endocrinology **126**:2868-2875. PMID: 2351099

79. Kano, K. and Jones, G. (1991) Alternate-day prednisolone treatment does not affect serum calcium or bone loss in vitamin D-depleted young rats. Dokkyo J. Med. Sci. **18**:17-22.

80. Chopra RK, Anastassiades T, Stephens C, Lohnes D, Jones G (1991) Newly synthesised glycoconjugates from two cell lines derived from rat osteogenic sarcoma: Effects of "matrigenin activity" from bone. Biochem Cell Biol **69**:49-57. PMID: 1904248

81. Jones G, Trafford DJH, Hollis BW, Makin HLJ (1991) Chapter 2: Vitamin D: Cholecalciferol Ergocalciferol and Hydroxylated Metabolites. In "Modern Chromatographic Analysis of the Vitamins", Second Edition. Chromatographic Science Series, Vol. 30 Eds. Nelis HJ, Lambert WE, De Leenheer AP; M. Dekker, New York and Basel, pp. 73-151.

82. Yendt ER, Cohanim M, Jarzylo SV, Jones G, Rosenberg G. (1991) Bone mass is related to creatinine clearance in normal, elderly women. J Bone Miner Res **6**:1043-1050. PMID: 1796752

83. Simboli, M. and Jones, G. (1991) Dietary phosphate deprivation increases renal synthesis and decreases renal catabolism of 1,25-dihydroxycholecalciferol in guinea pigs. J Nutr **121**:1635-1642. PMID: 1765829

84. Chopra RK, Anastassiades TP, Lohnes D, Jones G (1991) Further purification and characterization of newly synthesized anionic glycoconjugates secreted by cultured UMR-106 cells: evidence that the major anionic glycoconjugates secreted by these cells is similar to bone sialoprotein II. Biochem Cell Biol **69**:523-530. PMID: 1760156

85. Coldwell RD, Schroeder NJ, Jones G, Trafford DJH, Makin HLJ (1991) Use of gas chromatography-mass spectrometry for the measurement of dihydrotachysterol2 and two of its metabolites in human plasma. In: "Vitamin D. Gene Regulation, Structure-Function Analysis and Clinical Application". Eds. Norman AW, Bouillon R, Thomasset M; DeGruyter, Berlin and New York, pp. 650-651.

86. Mandla S, Tomon M, Byford V, Jones G, Tenenhouse HS (1991) Normal 24-hydroxylation of vitamin D metabolites in vitamin D dependency rickets Type I: Structural implications for the vitamin D hydroxylases. In: "Vitamin D. Gene Regulation, Structure-Function Analysis and Clinical Application". Eds. Norman AW, Bouillon R, Thomasset M; DeGruyter, Berlin and New York, pp. 273-274

87. Qaw F, Schroeder NJ, Calverley MJ, Jones G, Trafford DJH, Makin HLJ (1991) Catabolism of 1α,25-dihydroxydihydrotachysterol3 in vitro: comparison with in vivo generated metabolites of dihydrotachysterol3. In: "Vitamin D. Gene Regulation, Structure-Function Analysis and Clinical Application". Eds. Norman AW, Bouillon R, Thomasset M; DeGruyter, Berlin and New York, pp. 223-224.

88. Strugnell S, Bishop CW, Knutson JC, Jones G (1991) 24-hydroxylation of 1α-OH-D2 by cultured liver cells. In: "Vitamin D. Gene Regulation, Structure-Function Analysis and Clinical Application". Eds. Norman AW, Bouillon R, Thomasset M; DeGruyter, Berlin and New York, pp. 267-268.

89. Qaw F, Schroeder NJ, Calverley MJ, Trafford DJH, Makin HLJ, Jones G (1992). The metabolism of dihydro-tachysterols: renal side chain and non-renal nuclear hydroxylations *in vivo* and *in vitro*. J Steroid Biochem Mol Biol **41**:859-870. PMID: 1562563

90. Mandla S, Jones G, Tenenhouse HS (1992) Normal 24-hydroxylation of vitamin D metabolites in patients with vitamin D-dependency rickets Type I. Structural implications for the vitamin D hydroxylases. J Clin Endocrinol Metab **74**:814-820. PMID: 1548347

91. Qaw FS, Makin HLJ, Jones G (1992) Metabolism of 25-hydroxydihydrotachysterol3 in bone cells *in vitro*. Steroids, **57**:236-243. PMID: 1336906

92. Schroeder NJ, Qaw F, Calverley MJ, Trafford DJH, Jones G, Makin HLJ (1992) Polar metabolites of dihydrotachysterol3 in the rat: Comparison with *in vitro* metabolites of 1α,25-dihydroxydihydro-tachysterol3. Biochem Pharmacol **43**:1893-1905. PMID: 1596278

93. Lohnes D, Jones G (1992) Further metabolism of 1α,25-dihydroxyvitamin D3 in target cells. J Nutr Sci Vitaminol (Tokyo) Special No: 75-78. PMID: 1297826

94. Calverley MJ, Jones G (1992) Chapter 7: Vitamin D. In "Antitumor Steroids". Ed: Blickenstaff, RT; Academic Press Inc, Orlando, FL, pp. 193-270.

95. Calverley MJ, Strugnell S, Jones G (1993) The Seleno-acetal Route to 1α-Hydroxy-vitamin D Analogues: Synthesis of 24-Oxa-1α-hydroxy-vitamin D3, A Useful Vitamin D Metabolism Probe. Tetrahedron **49**:739-746.

96. Qaw F, Calverley MJ, Schroeder NJ, Trafford DJH, Makin HLJ, Jones G (1993) *In vivo* metabolism of the vitamin D analog, dihydrotachysterol: evidence for formation of 1α,25- and 1β,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem **268**:282-292. PMID: 8380156

97. Yendt ER, Cohanim M, Jarzylo S, Jones G, Rosenberg G. (1993) Reduced creatinine clearance in primary osteoporosis in women. J Bone Miner Res **8**:1045-1052. PMID: 8237473

98. Guo Y-D, Strugnell S, Back DW, Jones G (1993) Substrate specificity of the liver mitochondrial cytochrome P-450, CYP-27, towards vitamin D and its analogs. Proc Natl Acad Sci USA **90**:8668-8672. PMID: 7690968

99. Jones G, Calverley MJ (1993) A dialogue on analogues: Newer vitamin D drugs for use in bone disease, psoriasis and cancer. Trends Endocrinol Metab **3**:297-303. PMID: 18407173

100. Jones G (1994) Vitamin D target cells degrade 1α,25-(OH)2D3 and its analogues into inactive side chain shortened metabolites. "The Second International Forum on Calcified Tissue and Bone Disease: Vitamin D and its Analogues". Eds: Potts JT, Ogata E. Pub: Chugai Pharmaceutical Co Ltd, pp. 30-33.

101. Masuda S, Strugnell S, Calverley M, Makin HLJ, Kremer R, Jones G (1994) In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem **269**:4794-4803. PMID: 8106449

102. Dilworth FJ, Calverley MJ, Makin HLJ, Jones G (1994) Increased biological activity of 20-epi-1,25-dihydroxy-vitamin D3 is due to reduced catabolism and altered protein binding. Biochem Pharmacol **47**:987-993. PMID: 8147918

103. Schroeder NJ, Trafford DJH, Cunningham J, Jones G, Makin HLJ (1994) In vivo dihydrotachysterol2 metabolism in normal man: 1α- and 1β-hydroxylation of 25-hydroxydihydrotachysterol2 and effect on plasma parathyroid hormone & 1α,25-dihydroxyvitamin D3 concentration. J Clin Endocrinol Metab **78**:1481-1487. PMID: 8200953

104. Kovacs CS, Jones G, Yendt ER (1994) Primary hyperparathyroidism masked by antituberculous therapy-induced vitamin D deficiency. Clin Endocrinol (Oxf) **41**:831-836. PMID: 7889622

105. Dilworth FJ, Strugnell S, Guo YD, Calverley MJ, Makin HLJ, Jones G (1994) Site and rate of hydroxylation of 1α-OH-D3 analogs by CYP27 not altered by increasing length or changing orientation of vitamin D3 side chain. In: "Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications". Eds: Norman AW, Bouillon R, Thomasset M; De Gruyter, Berlin, pp.131-132.

106. Jones G, Lohnes D, Strugnell S, Guo Y-D, Masuda S, Byford V, Makin HLJ, Calverley MJ (1994) Target cell metabolism of vitamin D and its analogs. In: "Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications". Eds. Norman AW, Bouillon R, Thomasset M; de Gruyter, Berlin, pp.161-169.

107. Jones G, Byford V, Kremer R, Makin HLJ, Knutson JC, Bishop CW (1994) Novel cleavage of vitamin D2 side chain during catabolism by keratinocyte cell line. In: "Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications". Eds. Norman AW, Bouillon R, Thomasset M;

De Gruyter, Berlin, pp.188-189.

108. Masuda S, Byford V, Makin HLJ, Kremer R, Okano T, Kobayashi T, Kubodera N, Nishii Y, Jones G. (1994) 22-Oxacalcitriol is metabolized to C21 side-chain-cleaved products in both liver and target cells. In: "Vitamin D. A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications". Eds Norman AW, Bouillon R, Thomasset M; De Gruyter, Berlin, pp.190-191.

109. Meyer J, Galligan MA, Jones G, Komm BS, Haussler CA, Haussler MR (1995) 1,25(OH)2D3-dependent regulation of calbindin-D28k mRNA requires ongoing protein synthesis in chick duodenal organ culture. J Cell Biochem **58**: 315-327. PMID: 7593254

110. Dilworth FJ, Scott I, Green A, Strugnell S, Guo Y-D, Roberts EA, Kremer R, Calverley MJ, Makin HLJ, Jones G (1995) Different mechanisms of hydroxylation site selection by liver and kidney cytochrome P-450 species (CYP27 and CYP24) involved in vitamin D metabolism. J. Biol. Chem. **270**: 16766-16774. PMID: 7622489

111. Strugnell S, Byford V, Makin HLJ, Moriarty RM, Gilardi R, LeVan L, Knutson JC, Bishop CW, Jones G (1995) 1α,24S-Dihydroxyvitamin D2: A biologically active product of 1α-hydroxyvitamin D2 made in the human hepatoma, Hep3B. Biochem J **310**: 233-241. PMID: 7646451

112. Makin HLJ, Jones G, Calverley MJ (1995) Analysis of Vitamin D, its metabolites and structural analogues. In "Modern Analysis of Steroids". Eds: Makin HLJ, Gower DB, Kirk DN (deceased); Chapman & Hall pp.562-620.

113. Masuda S, Byford V, Kremer R, Makin HLJ, Kubodera N, Nishii Y, Okazaki A, Okano T, Kobayashi T, Jones G (1996). In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma and keratinocyte cell lines. J Biol Chem **271**:8700-8708. PMID: 8621502

114. Jones G, Byford V, Kremer R, Makin HLJ, Rice RH, deGraffenreid LA, Knutson JC, Bishop CA (1996) Anti-proliferative activity and target cell catabolism of the vitamin D analog, 1α,24(S)-dihydroxyvitamin D2 in normal and immortalized human epidermal cells. Biochem Pharmacol **52**:133-140. PMID: 8678897

115. Jones G (1996) Pharmacological Mechanisms of Therapeutics. Chapter 77. Vitamin D and analogs In: Principles of Bone Biology. Eds: Bilezikian J, Raisz L, Rodan G; Academic Press Inc, San Diego. pp 1069-1081.

116. Jones G, Hogan DB, Yendt ER, Hanley DA (1996). Vitamin D metabolites and analogs in the treatment of osteoporosis. Can Med Assoc J **155**:955-961. PMID: 8837546

117. Dilworth FJ, Black SM, Guo Y-D, Miller WL, Jones G (1996) Construction of a P450c27 fusion enzyme: A useful tool for analysis of vitamin D3-25-hydroxylase activity. Biochem J **320**:267-271. PMID: 8947497

118. White JA, Guo Y-D, Baetz K, Beckett-Jones B, Dilworth FJ, Jones G, Petkovich M (1996) Identification of the retinoic acid-inducible all-trans retinoic acid 4-hydroxylase. J Biol Chem **271**:29922-29927. PMID: 8939936

119. Shankar VN, Dilworth FJ, Makin HLJ, Schroeder NJ, Trafford DAJ, Kissmeyer A-M, Calverley MJ, Binderup E, Jones G (1997) Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side chain. Biochem Pharmacol **53**:783-793. PMID: 9113099

120. Kissmeyer A-M, Binderup E, Binderup L, Hansen CM, Andersen NR, Schroeder NJ, Makin HLJ, Shankar VN Jones G (1997) The metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro metabolites and their biological activities. Biochem Pharmacol **53**:1087-1097. PMID: 9175713

121. White JA, Beckett-Jones B, Guo Y-D, Dilworth FJ, Bonasaro J, Jones G, Petkovich M (1997) cDNA cloning of human retinoic acid metabolizing enzyme expressed in leukemia and breast carcinoma-derived cell lines. J Biol Chem **272:**18538-18541. PMID: 9228017

122. Jones G (1997) V. Basic Science of New Analogs. *Chapter 58: Analog Metabolism* in "Vitamin D" Eds. Feldman D, Glorieux F, Pike W. Academic Press, San Diego, CA, pp 973-994

1. Dilworth FJ, Williams GR, Kissmeyer A-M, Løgsted-Nielsen J, Binderup E, Calverley MJ, Makin HLJ, Jones G (1997) The vitamin D analog, KH1060 is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology, **138**: 5485-5496. PMID: 9389535
2. Jones G, Prosser D, Shankar VN, Dilworth FJ (1997) Metabolism of vitamin D and its analogs: Implications for mechanisms of analog action and cytochrome P450 structure. In: Vitamin D. Chemistry, biology and clinical applications of the steroid hormone. Eds: Norman AW, Bouillon R, Thomasset M; University of California, pp 147-154.

125. Kissmeyer A-M, Binderup E, Binderup L, Mork-Hansen C, Rastrup-Andersen N, Logsted-Nielsen J, Makin HLJ, Schroeder NJ, Shankar VN, Jones G (1997) In vivo and in vitro metabolism of the vitamin D analog EB1089. In: Vitamin D. Chemistry, biology &clinical applications of the steroid hormone. Eds: Norman AW, Bouillon R, Thomasset M; University of California, pp157-158.

126. Abu-Abed SS, Beckett BR, Chiba H, Chithalen JV, Jones G, Metzger D, Chambon P, Petkovich M (1998) Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by RARγ and RXRα. J Biol Chem **273**: 2409-2415. PMID: 9442090

1. Mawer EB, Jones G, Davies M, Still PE, Byford V, Schroeder NJ, Makin H.L.J, Bishop CW, Knutson JC (1998). Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-OH-D2 and 1α,24-(OH)2D2 detectable in human serum. J Clin Endocrinol Metab **83**: 2156-2166. PMID: 9626155
2. Jones G, Strugnell S, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiological Reviews **78**:1193-1231. PMID: 9790574

129. Jones G (1998) Chapter 4: Metabolism and catabolism of vitamin D, its metabolites and clinically relevant analogs. In "Vitamin D: Physiology, Molecular Biology, Physiology and Clinical Applications" Ed. Holick MF. Humana Press, Totowa NJ, 57-84. **Doody Award Winner for top 250 medical science books in 2000**

130. Jones G, Ramshaw H, Zhang A, Cook R, Byford V, White J, PetkovichM(1999)Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1α and CYP24) in human non-small cell lung carcinomas. Endocrinology **140:** 3303-3310. PMID: 10385427

131. Masuda S, Kamao M, Schroeder NJ, Makin HLJ, Jones G, Kremer R, Rhim J, Okano T (2000) Characterization of 3-epi-1,25-Dihydroxyvitamin D3 Involved in 1,25-Dihydroxyvitamin D3 Metabolic Pathway in Cultured Cell Lines. Biol Pharm Bull **23**: 133-139. PMID: 10706373

132. Van Den Bemd GJ-CM, Dilworth FJ, Makin HLJ, Prahl JM, DeLuca HF, Jones G, Pols HAP, Van Leeuwen JPTM (2000) Contribution of several metabolites of the vitamin D analog 20-epi-22-oxa-24a,26a,27a-trihomo-1,25-(OH)2vitamin D3 (KH1060) to the overall biological activity of KH1060 by a shared mechanism of action. Biochem Pharmacol **59**:621-627. PMID: 10677578

133. Jones G, Makin HLJ (2000) Chapter 2: Vitamin D in "Modern Chromatographic Analysis of the Vitamins"

Third Edition. Eds: Van Bocxlaer J, Lambert W, De Leenheer A; Marcel Dekker, New York, pp75-141.

134. White JA, Ramshaw H, Taimi M, Stangle W, Zhang A, Everingham S, Creighton S, Tam S-P, Jones G, Petkovich M (2000) Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-*trans* retinoic acid metabolism. Proc Natl Acad Sci USA. **97**:6403-6408. PMID: 10823918

135. Jones G, Byford V, Prosser D, Makin HLJ, St Arnaud R, Demay M, Knutson JC, Strugnell S, Bishop CW (2000) New approaches for the study of vitamin D metabolism. In: Vitamin D endocrine System: Structural, Biological, Genetic and Clinical Aspects. Eds: Norman AW, Bouillon R, Thomasset M, University of California Press, pp135-142.

136 Jones G (2000) Part IV The Nutrients- Deficiencies, Surfeits & Food-Related Disorders: Part IVA4: Vitamin D. In: "The Cambridge World History of Food". Eds. Kiple KF, Ornelas KC. Published by University of Cambridge Press, Cambridge UK, pp.763-768.

137. Jones, G (2000) Part IV The Nutrients- Deficiencies, Surfeits & Food-Related Disorders: Part IVA5: Vitamin E. In: "The Cambridge World History of Food". Eds. Kiple, KF, Ornelas KC. Published by University of Cambridge Press, Cambridge UK, pp.769-774.

138. Gascon-Barre M, Demers C, Ghrab O, Theodoropoulos C, Lapointe R, Jones G, Valiquette L, Menard D (2001) Expression of CYP27A, a gene encoding a vitamin D-25-hydroxylase in human liver and kidney. Clin Endocrinol (Oxf) **54**:107-115. PMID: 11167933

139. Shankar VN, Propp AE, Schroeder NS, Surber BW, Makin HLJ, Jones G (2001) *In vitro* metabolism of 19-nor-1α,25-(OH)2D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites. Arch Biochem Biophys **387**: 297-306. PMID: 11370854

140. Shankar VN, Byford V, Prosser DE, Schroeder NJ, Makin HLJ, Wiesinger H, Neef G, Steinmeyer A, Jones G (2001) Metabolism of a 20-methyl substituted series of vitamin D analogs by cultured human cells: Apparent reduction of 23-hydroxylation of the side chain by 20-methyl group. Biochem Pharmacol **61**: 893-902. PMID: 11274975

1. Luu L, Ramshaw H, Tahayato A, Stuart A, Jones G, White J, Petkovich M (2001) Regulation of retinoic acid metabolism. Adv Enzyme Regul **41**:159-175. PMID: 11370854
2. Prosser DE, Jones G (2001)Vitamin D and its analogs. Current Medicinal Chemistry-Immunology, Endocrine & Metabolic Agents, **1:**217-234.
3. Jones G (2002) Chapter 81. Pharmacological Mechanisms of Therapeutics: Vitamin D and analogs. In: *Principles of Bone Biology*. Second Edition, Volume 2. Eds: Bilezikian J, Raisz L, Rodan G, Academic Press Inc, San Diego. pp 1407-1422.
4. Jones G, Tenenhouse HS (2002) 1,25-(OH)2D: preferred substrate for CYP24? Letter to the Editor. J Bone Miner Res **17**:179-180. PMID: 11774846
5. Prosser DE, Jones G (2002)Molecular Actions of Vitamin D and its analogs. In: *Modern Trends in Skin Pharmacology*, Eds. Tsambaos D, Merk H; Parissianos Medical Publications, Athens, Greece. pp 1-21.
6. Klein GL, Soriano H, Shulman RJ, Levy M, Jones G, Langman CB (2002) Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant **6:**136-140. PMID: 12000470

147. Chithalen JV, Luu L, Petkovich M, Jones G (2002) HPLC/MS-MS analysis of the products generated from all-*trans* retinoic acid using recombinant human CYP26A. J Lipid Res **43**:1133-42. PMID: 12091498

148. Byford V, Strugnell S, Coldwell R, Schroeder N, Makin, HLJ, Knutson JC, Bishop CW, Jones G (2002). Use of Vitamin D4 Analogs to investigate Differences in Hepatic and Target Cell Metabolism of Vitamins D2 and D3. Biochim Biophys Acta **1583**:151-66. PMID: 12117559

149. Jones G (2002). Chapter 8:Vitamin D from “Human Vitamin and Mineral Requirements” a Report of a Joint FAO/WHO Guide for Dietary Intakes of Vitamins and Minerals. Suggested worldwide guidelines derived from working group convened by WHO/FAO in Bangkok, Sept. 1998. (Contributing co-author).

150. Masuda S, Jones G (2003) Vitamin D Analogs: Drug design based upon proteins involved in vitamin D signal transduction. Current Drug Targets-Immune, Endocr Metabol Disord **3**:43-67. PMID: 12570725

151. Masuda S, Gao M, Zhang A, Kaufmann M, Jones G (2003) Importance of Cytochrome P450-mediated metabolism in the mechanism of action of vitamin D analogs. Recent Results Cancer Res **164**:189-202. PMID: 12570725

152. Chuang SS, Helvig C, Taimi M, Ramshaw HA, Collop AH, Amad M, White JA, Petkovich M, Jones G, Korczak B (2004) CYP2U1, a novel human thymus and brain specific cytochrome P450 catalyzes ω- and

(ω-1)-hydroxylation of fatty acids. J Biol Chem **279**:6305-6314. PMID: 14660610

153. Posner GH, Crawford KR, Yang HW, Kahraman M, Jeon HB, Li H, Lee JK, Suh BC, Hatcher MA, Labonte T, Usera A, Dolan PM, Kensler TW, Peleg S, Jones G, Zhang A, Korczak B, Saha U, Chuang SS (2004) Potent low-calcemic selective inhibitors of CYP24 hydroxylase: 24-sulphone analogs of the hormone 1α,25-dihydroxy vitamin D3. J Steroid Biochem Mol Biol, **89-90**, 5-12. PMID: 15225738

154. Masuda S, Kaufmann M, Byford V, Gao M, St-Arnaud R, Arabian A, Makin HLJ, Knutson JC, Strugnell S, Jones G (2004) Insights into vitamin D metabolism using CYP24 over-expression and knockout systems in conjunction with liquid chromatography/mass spectrometry (LC/MS). J Steroid Biochem Mol Biol, **89-90**,149-153. PMID: 15225763

155. Carter GD, Carter CR, Gunter E, Jones J, Jones G, Makin HLJ, Sufi S (2004) Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol **89-90**, 467-471. PMID: 15225822

156. Prosser DE, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci **29**:664-73. PMID: 15544953

1. Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St-Arnaud R, Jones G (2005) Altered Pharmacokinetics of 1α,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) null mouse. Endocrinology **146**:825-34. PMID: 15498883
2. Jones G (2005) Chapter 81: “Analog Metabolism”. In: “Vitamin D 2nd Edition”. Eds Feldman D, Pike W, Glorieux F; Academic Press, San Diego, CA pp 1423-1448.
3. Jellinck PH, Croft G, McEwen BS, Gottfried-Blackmore A, Byford V, Jones G, Bulloch K (2005) Metabolism of Dehydroepiepiandrostene by rodent brain cell lines: Relationship between 7-hydroxylation and aromatization,. J Steroid Biochem Mol Biol **93**:81-86. PMID: 15748836
4. Jellinck PH, Kaufmann M, Gottfried-Blackmore A, Croft G, Byford V, McEwen BS Jones G, Bulloch K (2006) Dehydroepiepiandrostene (DHEA) metabolism in the brain: Identification by LC-MS of the Δ4-isomer of DHEA and related steroids from androstenedione by mouse BV2 microglia. J Steroid Biochem Mol Biol **98**:41-47. PMID: 16203131
5. Masuda S, Strugnell S, Knutson JC, St-Arnaud R, Jones G (2006) Evidence for the activation of 1α-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1α,24-dihydroxyvitamin D2 & 1α,25-dihydroxyvitamin D2. Biochim Biophys Acta **1761**:221-234. PMID: 16516540

162. Prosser DE, Guo Y-D, Geh KR, Jia Z, Jones G (2006) Molecular modelling of CYP27A1 and site-directed mutational analyses affecting vitamin D hydroxylation. Biophys J **90**:1-21. PMID: 16500955

163. Masuda S, Jones G (2006) The promise of vitamin D analogs in the treatment of hyperproliferative conditions. Mol Cancer Ther **5**:797-808. PMID: 16648549

1. Jones G, Byford V, West S, Masuda S, Ibrahim G, Kaufmann M, Knutson J, Strugnell S, Mehta R. (2006)Hepatic Activation & Inactivation of Clinically-Relevant Vitamin D Analogs and Prodrugs. Anticancer Res **26**:2589-2596. PMID: 16886668
2. Masuda S, Prosser D, Guo Y-D, Kaufmann M, Jones G (2007) Generation of a homology model for the human cytochrome P450, CYP24A1, and the testing of putative substrate binding residues by site-directed mutagenesis and enzyme activity studies. Arch Biochem Biophys **460**:177-191. PMID: 17224124
3. Forkert P-G, Kaufmann M, Black G, Bowers R, Chen H, Collins K, Sharma A, Jones G (2007) Oxidation of vinyl carbamate and formation of 1-N6-ethenodeoxyadenosine in murine lung. Drug Metabolism and Disposition **35**: 713-720. PMID: 17296623
4. Jones G (2007) Expanding role for vitamin D in chronic kidney disease: Importance of blood 25-OH-D levels & extra-renal 1α-hydroxylase in the classical and non-classical actions of 1α,25-dihydroxyvitamin D3. Semin Dial **20**: 316-324. PMID: 17635821
5. Prosser D, Kaufmann M, O’Leary B, Byford V, Jones G (2007) Single A326G mutation converts hCYP24A1 from a 25-OH-D3-24-hydroxylase into -23-hydroxylase generating 1α,25-(OH)2D3-26,23-lactone. Proc Natl Acad Sci USA **104**:12673-12678. PMID: 17646648
6. Jellinck PH, Kaufmann M, Gottfried-Blackmore A, McEwan BS, Jones G, Bulloch K (2007) Selective conversion by microglia of dehydroepiandrosterone to 5-androstenediol-a steroid with inherent estrogenic properties. J Steroid Biochem Mol Biol **107**:156-162. PMID: 17681749
7. Jones G, Horst RL, Carter G, Makin HLJ (2007). Contemporary Diagnosis and Treatment of Vitamin D-related Disorders. J Bone Miner Res **22 (Suppl 2)**:V11-V15. PMID: 18290713

171. Yendt E, Kovacs KA, Jones G (2008) Secondary Hyperparathyroidism in Primary Osteoporosis and Osteopenia: Optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction. Clin Endocrinol (Oxf) **69**:855-63. PMID: 18419790

172. Strushkevich N, Usanov SA, Plotnikov AN, Jones G, Park H-W (2008) Structural Analysis of CYP2R1 in complex with vitamin D3. J Mol Biol **380**:95-106. PMID: 18511070

173. Nowickyj SM, Chithalen JV, Cameron D, Tyshenko MG, Petkovich M, Wyatt GR, Jones G, Walker V (2008) Locust retinoid X receptors: 9-*cis* retinoic acid in embryos from a primitive insect. Proc Natl Acad Sci USA **105**: 9540-9545. PMID: 18606996

174. Jones G (2008) Pharmacokinetics of Vitamin D Toxicity. Amer J Clin Nutr **88**: 582S-586S. PMID: 18689406

175. Jones G (2008) Chapter 83: Vitamin D and Analogues. In: *Principles of Bone Biology*. Third Edition. Section: Pharmacological Mechanisms of Therapeutics. Eds: Bilezikian J, Raisz L, Rodan G, Academic Press Inc, San Diego. pp 1777-1799.

176. Carter GD, Berry JL, Gunter E, Jones G, Jones JC, Makin HLJ, Sufi S, Wheeler MJ (2010) Proficiency Testing of 25-hydroxyvitamin D (25-OH-D) assays. J Steroid Biochem Mol Biol **121**:176-179. PMID: 20302938

177. Jones G (2010) Editorial: Why Dialysis Patients need combination therapy with cholecalciferol and a calcitriol analog. Semin Dial **23**:239-43. PMID: 20492584

178. Jones G (2010) Vitamin D analogs. Endocrinol Metab Clin North Am **39**:447-472. PMID: 20511062

179. Makin HLJ, Jones G, Kaufmann M, Calverley M (2010) Chapter 11: Analysis of Vitamins D, their metabolites & analogues. In: "*Steroid Analysis, Second Edition*". Eds: Makin HLJ, Gower DB; Springer (Chapman & Hall) pp 967-1094.

180. Jones G (2010) Chapter 4: Functional Metabolism of Vitamin D, its Metabolites and Clinically Relevant Analogs in “*Vitamin D: Physiology, Molecular Biology and Clinical Applications, 2nd Edition*”, Humana Press, Totawa NJ. Ed: Holick MF. pp 99-134.

181. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C (2010) [Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada.](http://www.ncbi.nlm.nih.gov/pubmed/20624868) CMAJ **182**:E610-618. PMID: 20624868

182. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD (2010) [Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada - summary.](http://www.ncbi.nlm.nih.gov/pubmed/20624865) CMAJ **182**:1315-1319. PMID: 20624865

183. Arboraia AS, Yee SW, Gomaa MS, Shah N, Robotham AC, Makowski B, Prosser D, Brancale A, Jones G, Simons C (2010). Synthesis and CYP24A1 inhibitory activity of *N*-(2-(1*H*-imidazol-1-yl)-2-phenylethyl) aryl amides. Bioorganic & Medicinal Chemistry. **18**:4939-46. PMID: 20594862

184. Arboraia AS, Makowski B, Bahja A, Prosser D, Brancale A, Jones G, Simons C (2010) Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substututed benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones. European J Med Chemistry **45**:4427-4434. PMID: 20655626

185. Ross AC, Manson JE, Taylor CL, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses S (2011) The 2011 IOM Report on Vitamin D and Calcium: What Physicians Need to Know. J Clin Endocrinol Metab **96**:53-58. PMID: 21118827

186. Ross AC, Manson JE, Brannon PM, Taylor CL, Abrams SA, Aloia JF, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses S (2011) “The 2011 Dietary Reference Intakes for Vitamin D and Calcium”. Institute of Medicine, National Academy of Sciences. NAS Press, Washington DC USA. March 31 2011 pp 1-1075.

187. Jones G, Prosser DE (2011) Chapter 3: The Activating Enzymes of Vitamin D Metabolism (25- and1α-hydroxylases). In: 3rd Edition of "*Vitamin D*". Eds: Feldman D, Pike W, Adams J; Elsevier, San Diego, CA pp 23-42

188. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses S (2011) The 2011 Dietary Reference Intakes for Vitamin D and Calcium: What Dietetics Practitioners Need to Know. J Amer Dietetic Assoc **111**:524-527. PMID: 21443983

189. Petkovich MP, Jones G (2011) CYP24A1 and chronic kidney disease. Curr Opin in Nephrol Hypertens **20**: 337-344. PMID: 21610497

190. Gambhir V, Kim J, Siddiqui S, Taylor M, Byford V, Petroff EO, Jones G, Basta S (2011): Influence of 1,25-Dihydroxyvitamin D3 on TLR-induced activation of the antigen presenting cells is dependent on the order or receptor engagement. Immunobiology **216**:988-96. PMID: 21529994

191. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, Misselwitz J, Klaus G, Kuwertz-Broking E, Fehrenbach H, Wingen AM, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M. (2011) Mutations of CYP24A1 and Idiopathic Infantile Hypercalcemia. New Engl J Med **365**:410-421. PMID: 21675912

192. Kaufmann M, Prosser D, Jones G (2011) Bioengineering anabolic vitamin D-25-hydroxylase activity into the human vitamin D catabolic enzyme, hCYP24A1 by a V391L mutation. J Biol Chem **286**:28729-28737. PMID: 21697097

193. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. (2011) [Clarification of DRIs for Calcium and Vitamin D across Age Groups.](http://www.ncbi.nlm.nih.gov/pubmed/21963009) J Am Diet Assoc. **111**:1467. PMID: 21963009

194. Helvig C, Taimi M, Cameron D, Jones G, Petkovich M (2011) Functional properties and substrate characterization of human CYP26A1, CYP26B1 and CYP26C1 expressed by recombinant baculovirus in insect cells. J Pharmacol Toxicol Methods. **64**:258-263. PMID: 21906690

195. Schlingmann KP, Jones G, Konrad M. (2011) Mutations of CYP24A1 in Idiopathic Infantile Hypercalcemia. New Engl J Med **365**:1741-1743 (Author’s Reply to Letters to the Editor).

196. Jones G, Kaufmann M, Prosser D (2012) 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys **523**:9-18. PMID: 22100522

197. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Ross AC, Shapses SA, Taylor C. IOM Committee members respond to Endocrine Society Vitamin D Guideline (2012). J Clin Endocrinol Metab **97**:1146-1152. PMID: 22442278

198. Jones G (2012) Vitamin D Analogs. Rheum Disease Clinics N America **38**:207-32. PMID: 22525852

199. Jones G (2012) Metabolism and Biomarkers of Vitamin D. Scand J Clin Lab Invest Suppl **243**:7–13. PMID: 22536757

200. Jones G (2012) 2.16: Biochemistry and Metabolism of Vitamin D. *In:* Adv in Clin Chem & Lab Med. Eds: Renz H, Tauber R; De Gruyter, Berlin; pp 78-81.

201. Jones G (2012) Chapter 3: Vitamin D analogs and their clinical uses. In: *Vitamin D:  Oxidation, Immunity & Aging*. Ed: Adrian F. Gombart; Taylor & Francis Group, CRC Press. Boca Raton, FL, pp 65-98.

202. Jones G (2012) Chapter 18: Vitamin D. In: “*11th Edition of Modern Nutrition in Health and Disease”* Ed: Cousins RJ. Published by Lippincott, Williams and Wilkins, pp 278-292; published Dec 18 2012.

203. Clinton SK, Albanes D, Fleet JC, Jones G, Mayne S (2013) Vitamin D and Cancer: Visions of Panacea or Icarus? Nutrition Today **48**:42-46.

204. Jones G, Prosser DE, Kaufmann M (2014) Cytochrome P450-mediated Metabolism of Vitamin D. J Lipid Res **55:**13-31.Thematic Mini-review Series: Fat-Soluble Vitamins. Ed: Blaner WS; [epub April 6 2013, ahead of print] PMID: 23564710. Figure from article used for journal cover art.

205. Gallo S, Comeau K, Vanstone C, Agellon S, Sharma A, Jones G, L’Abbe M, Khamsessen A, Rodd C, Weiler H. (2013) Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy breastfed infants: A randomized trial. JAMA **309**:1785-1792. PMID: 23632722

206. Jones G (2013) Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3 and vitamin D analogs. Annual Review of Nutrition **33:**23-44. [epub April 29 2013 ahead of print]; PMID: 23642201

207. Zhu J, Ochalek JT, Kaufmann M, Jones G, DeLuca HF (2013). *CYP2R1* is a major, but not exclusive, contributor to 25-hydroxyvitamin D production *in vivo*. Proc Natl Acad Sci USA **110**: 15650-15655. [epub August 15, 2013 ahead of print]; PMID: 24019477

208. Jacobs TP, Kaufmann M, Jones G, Kumar R, Schlingmann K, Shapses S, Bilezekian JP (2014) A lifetime of hypercalcemia and hypercalciuria finally explained. J Clin Endocrinol Metab **99**:708-712. [epub January 13, 2014] PMID: 24423361

209. Gallo S, Comeau K, Agellon S, Vanstone C, Sharma A, Jones G, L’Abbe M, Khamessan A, Weiler H, Rodd C. (2014) Methodological issues in assessing plasma 25-hydroxyvitamin D concentration in newborn infants.

Bone **61C**:186-190. [epub January 25 2014, ahead of print] PMID: 24473373

210. Wallingford SC, Jones G, Kobayashi LC, Grundy A, Miao Q, Tranmer J, Aronson KJ (2014) UV and dietary predictors of serum 25-hydroxyvitamin D concentrations among young shift-working nurses and implications for bone density and skin cancer. Public Health Nutr. **17**:772-779. [Epub 2013 July 9]; PMID: 23835190

211. Kaufmann M, Gallagher C, Peacock M, Schlingmann K-P, KonradM, DeLuca HF, Sigueiro R, Lopez B, Mourino A, Maestro M, St-Arnaud R, Finkelstein J, Cooper DP, Jones G. (2014) Clinical Utility of Simultaneous Quantitation of 25-hydroxyvitamin D & 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD. J Clin Endocrinol Metab **99**:2567-2574. [epub March 26 2014]; PMID:24670084.

212. Jones G (2015) Interpreting 25-Hydroxyvitamin D Assay Results: Proceed with Caution. Clin J Amer Soc Nephrol, Invited Commentary. **10**:331-334 [epub. August 8 2014] PMID: 25107951.

213. St-Arnaud R, Jones G, Glorieux FH. (2015) Chapter 67: Genetic defects in vitamin D metabolism and action In: Endocrinology: Adult and Pediatric, 7th Edition. Ed. Jameson JL, DeGroot LJ, Saunders-Elsevier, New York

214. Cashman KD, Hayes A, Galvin K, Merkel J, Jones G, Kaufmann K, Hoofnagle A, Carter GD, Durazo-Arvizu RA, Sempos CT (2015) Significance of serum 24,25-dihydroxyvitamin D in the assessment of vitamin D status:

a double-edged sword. Clin Chem **61**:636-645 [epub February 20 2015]. PMID: 25710460

215. Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, Patti M, Kranz B, Pronicka E, Ciara E, Akcay T, BulusD, Cornelissen EA, Gawlik A, Sikora P, Patzer L, Galiano M, Boyadzhiev V, Dumic M, Vivante A, Kleta R, Dekel B, Levtchenko E, Bindels RJ, Rust S, Stoll M, Forster IC, HernandoN, Jones G, Wagner CA, Konrad M (2016) Autosomal-recessive mutations in SLC34A1 encoding sodium-phosphate cotransporter 2A cause Idiopathic Infantile Hypercalcemia. J Amer Soc Nephrology **27**:604-614 [epub June 5 2015]. PMID: 26047794

216. Shah AD, Hsiao EC, O’Donnell B, Salmeen K, Nussbaum R, Krebs M. Baumgartner-Parzer S, Kaufmann M, Jones G, Bikle DD, Wang, YM, Mathew AS, Shoback D, Block-Kurbisch I (2015) Maternal Hypercalcemia due to Failure of 1,25-dihydroxyvitamin D3 Catabolism in a Patient with *CYP24A1* Mutations.

J Clin Endocrinol Metab **100**:2832-6 [epub June 22 2015]. PMID: 26097993

217. Wicklow B, Gallo S, Majnemer A, Vanstone C, Sharma A, Jones G, L’Abbe M, Khamessan A, Weiler H,

Rodd C. (2016) Impact of Vitamin D Supplementation on gross motor development of healthy term infants:

a randomized dose response trial. Physical & Occupational Therapy in Pediatrics **36**:330-342 [epub Early Online:1-13, September 1 2015] PMID: 26325246

218. Molin A, Bandoin R, Kaufmann M, Souberbielle JC, Ryckewaert A, Vanthygem MC, Eckart P, Bacchetta J, Deschenes G, Kesler-Roussey G, Coudray N, Richard N, Wraich M, Bonafiglia Q, Tiulpakov A, Jones G, Kottler M-L (2015) *CYP24A1* Mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J Clin Endocrinol Metab **100**: E1343-E1352 [epub July 27 2015]. PMID: 26214117

219. Jones G (2015) Biomarkers of Vitamin D Metabolism: Current State of Knowledge. Standardy Medyczne/Pediatria **12**:800-804.

220. Kaufmann M, Lee SM, Pike JW, Jones G (2015) A high-calcium, and phosphate rescue diet and VDR-expressing transgenes normalize serum vitamin D metabolite profiles and renal *CYP27B1* and *CYP24A1* expression in VDR-null mice. Endocrinology **156**:4388-4397 [epub October 6 2015]. PMID: 26441239

221. Hanson C, Jones G, Lyden E, Kaufmann M, Armas L, Anderson-Berry A (2016) Vitamin D metabolism in the premature newborn: a randomized trial. Clinical Nutrition. **35**:835-841[epub August 13 2015] PMID: 26302850

222. Hanson C, Anderson-Berry A, Lyden E, Kaufmann M, Wu A, Elliott E, Lee J-I, Jones G (2016) Dynamics of Vitamin D Metabolism in Maternal-Fetal Dyads. Journal of Pediatric Gastroenterology & Nutrition **62**:486-490. [epub October 23 2015] PMID: 26513621

223. Gallo S, Hazell T, Vanstone CA, Agellon S, Jones G, L’Abbe M, Rodd C, Weiler HA. (2016) Vitamin D Supplementation in infancy: Bone health affects at 3 years of age in a prospective follow-up study from Montreal, Canada. Osteoporosis International **27**:2459-2466 [epub March 11 2016]. PMID: 26968165

224. Jones G, Kaufmann M (2016) Vitamin D metabolite profiling using liquid-chromatography-tandem mass spectrometry (LC-MS/MS). J Steroid Biochem & Mol Biol. **164**:110-114 [epub September 26 2015].

PMID: 26409684

225. Carter GD, Jones JC, Shannon J, Williams EL, Jones G, Kaufmann M, Sempos C (2016) 25-hydroxyvitamin D assays: Potential interference from other circulating metabolites. J Steroid Biochem & Mol Biol, **164**:134-138 [epub December 21 2015]. PMID: 26718874

226. Baudart P, Molin A, Cesini J, Jones G, Kaufmann M, Kottler ML, Marcelli C (2017) [Calcium pyrophosphate deposition disease revealing a hypersensitivity to vitamin D.](https://www.ncbi.nlm.nih.gov/pubmed/28109821) Joint Bone Spine. **84**:349-351. [epub January 18 2017] PMID: 28109821

227. Kaufmann M, Morse N, Molloy BJ, Cooper D, Schlingmann K-P, Molin A, Kottler M-L, Gallagher JC, Armas L, Jones G (2017) [Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2 D3 in Affected Patients.](https://www.ncbi.nlm.nih.gov/pubmed/28304097) J Bone Mineral Res. **32**:1589-1596. [Epub April 21 2017] PMID: 28304097

# 228. Molin A, Wiedemann A, Demers N, Kaufmann M, Do Cao J, Mainard L, Dousset B, Journeau P, Abeguile G, Coudray N, Mittre H, Richard N, Weryha G, Sorlin A, Jones G, Kottler ML, Feillet F (2017) Vitamin D-Dependent Rickets Type 1B (25-Hydroxylase Deficiency): A Rare Condition or a Misdiagnosed Condition? J Bone Mineral Res. 32:1893-1899. [Epub July 13 2017] PMID: 28549923

229. Gorman S, Zafir M, Lim EM, Clarke M, Dhamrait G, Fleury N, Walsh J, Kaufmann M, Jones G, Lucas R. (2017) High dose intramuscular vitamin D provides long-lasting moderate increases in serum 25-hydroxvitamin D levels and shorter-term changes in plasma calcium. J AOAC Int. **100:**1337-1344 [epub May 11 2017]. PMID: 28492140

230. Wise SA, Tai SS-C, Nelson M, Burdette C, Hoofnagle A, Laha TJ, Carter GD, Jones J, Williams E, Barclay Z, Jones G, Kaufmann M, Binkley NC, Kapoor A, Ziegler T, Cashman KD, Dowling K, Sempos CT (2017) Interlaboratory Comparison for the Determination of 24R,25-Dihydroxyvitamin D3 in Human Serum using Liquid Chromatography with Tandem Mass Spectrometry. J AOAC Int. **100**:1308-1317. [epub July 24 2017] PMID: 28741469.

231. Anderson-Berry A, Thoene M, Wagner J, Lyden ER, Kaufmann M, Jones G, Hanson CK (2017) Randomized Trial of Two Doses of Vitamin D3 in Preterm Infants <32 Weeks: Dose Impact on Achieving Desired Serum 25(OH)D in NICU Populations. PLoS One **12**(10):e0185950. [Epub October 10 2017] PMID: 29016653

232. Meyer MB, Benkusky NA, Kaufmann M, Lee SM, Onal M, Jones G, Pike JW. (2017) A kidney-specific genetic control module in mice governs endocrine regulation of the cytochrome P450 gene Cyp27b1 essential for vitamin D3 activation. J Biol Chem. **292**:17541-17558 [Epub August 14 2017] PMID: 28808057.

**JBC Editor’s Pick Issue 42, 2017.**

233. Jones G, Kottler M-L, Schlingmann KP (2017) Genetic diseases of vitamin D Metabolizing Enzymes. Endocrinology and Metabolism Clinics of North America. **46**:1095-1117 [Epub. April 13 2017]

PMID: 29080636

234. Carter GD, Berry J, Durazo-Arvizu R, Gunter E, Jones G, Jones J, Makin HL, Pattni P, Phinney KW, Sempos CT, Williams EL. (2017) Quality Assessment of vitamin D metabolite assays used by clinical and research laboratories. J Steroid Biochem Mol Biol. **173**:100-104 [Epub. March 15 2017] PMID: 28315391

235. Jones G, Prosser DE, Kaufmann M (2017) Chapter 5: The Activating Enzymes of Vitamin D Metabolism (25- and 1α-hydroxylases). In: 4th Edition of "*Vitamin D*". Eds: Feldman D, Pike W, Bouillon R, Giovannucci E, Goltzman D, Hewison M; Elsevier, San Diego, CA. Published 14 December 2017.

236. St-Arnaud R, Jones G (2017) Chapter 6: CYP24A1: Structure, Function and Physiological Role. In: 4th Edition of "*Vitamin D*". Eds: Feldman D, Pike W, Bouillon R, Giovannucci E, Goltzman D, Hewison M; Elsevier, San Diego, CA. Published 14 December 2017.

**Manuscripts ePub or In Press**

237. Djekic-Ivankovic M, Weiler H, Jones G, Kaufmann M, Kaludjerovic J, Aleksic-Velickovic V, Mandic L, Glibetic M (2016) Vitamin D status in mothers with preeclampsia and their infants: a case control study from Serbia, a country without vitamin D fortification policy. Public Health Nutrition pp1-11, [epub April 18 2016]

PMID: 27087002

238. Turner M, Laverty K, Jeronimo P, Kaufmann M, Jones G, White C, Holden R, Adams M. (2017) Validation of a routine two-sample iohexol plasma clearance assessment of GFR and evaluation of common endogenous markers in a rat model of CKD. Physiological Reports. [Epub. May 5 2017] PMID: 28483858

239. Graeff-Armas LA, Kaufmann M, Lyden E, Jones G (2017) Serum 24,25-Dihydroxyvitamin D3 response to native vitamin D2 and D3 supplementation in patients with chronic kidney disease on hemodialysis. Clin Nutr. Manuscript accepted April 24 2017. PMID: 28506446

240. Jones G, Schlingmann K-P (2018) Chapter: Hypercalcemic States Associated with Abnormalities in Vitamin D Metabolism. In: “Emerging Aspects of Vitamin D in Clinical Medicine”. Frontiers of Hormone Research. **50**: 1-25. Eds: Bilezikian JP, Giustina A. Karger, Basel, Switzerland. Review in press, accepted February 28, 2017

241. CarterGD, Berry J, Durazo-Arvizu R, Gunter E, Jones G,Jones J, Makin HLJ, Pattni P, Sempos CT, TwomeyP, Williams EL, WiseSA. (2017) Hydroxyvitamin D Assays: an historical perspective from DEQAS. J Steroid Biochem & Mol Biol. S0960-0760(17)30183-8. doi: 10.1016/j.jsbmb.2017.07.018. [Epub July 19 2017] PMID: 28734989

242. Silvestre C, Aragues JM, Bughalho MJ, Jones G, Kaufmann M. Idiopathic infantile hypercalcemia: presenting in childhood, diagnosed in adulthood. American Association of Clinical Endocrinologists (AACE) Clinical Case Reports. Manuscript accepted November 12 2017, in press.

243. Brett NR, Parks CA, Lavery P, Agellon S, Vanstone C, Kaufmann M, Jones G, Maguire JL, Rauch F, Weiler H (2017) Vitamin D status and functional health outcomes in 2-8 yr old healthy children: a 6 month randomized vitamin D trial using fortified foods. J Clin Endocrinol Metab. Manuscript accepted December 7 2017, in press.

244. Baudart P, Molin A, Cesini J, Jones G, Kaufmann M, Kottler ML, Marcelli C (2017) [Chondrocalcinose articulaire relevant une hypersensibilite a la vitamine D.](https://www.ncbi.nlm.nih.gov/pubmed/28109821) Revue du Rhumatisme **84**:551-553. [epub March 31 2017] PMID: 28109821

245. Jones G (2018) The Discovery and Synthesis of the Nutritional Factor, Vitamin D. Special issue on Vitamin D. International Journal Paleopathology, Manuscript in Press; [Epub. January 17 2018].

**Manuscripts Submitted, Under Review or In Preparation**

246. Delvin E, Boisvert M, Lecours, M-A, Théorêt Y, Levy E, Kaufmann M, Jones G. Supporting data for the measurement of serum vitamin D metabolites in childhood acute lymphoblastic leukemia survivors.

Elsevier Data in Brief. Manuscript submitted December 28 2017.

247. Jones G, Pike JW. Chapter X: Vitamin D and Analogues. In: Principles of Bone Biology, Fourth Edition.

Eds: Bilezikian J, Martin JT, Clemens TL, Rosen CJ. Elsevier, San Diego, CA. Invited chapter due December 2017.

248. Carlson AH, Lee SM, Benkusky NA, Kaufmann M, St-Arnaud R, Jones G, Meyer MB, Pike JW (2018) Mouse and Human CYP24A1 Transgenes Rescue the *Cyp24a1*-null Mouse Phenotype and Restore Vitamin D Metabolism in Target Tissues. Manuscript under revision January 2018.

249. Smith LM, Gallagher JC, Kaufmann M, Jones G (2018) Effect of Increasing Doses of Vitamin D on Bone Mineral Density and Bone Markers in Elderly Women: A Randomized Trial. Manuscript under revision January 2018.

250. Marcinowska-Suchowierska E, Kupisz-Urbańska M, Łukaszkiewicz J, PłudowskiP,Jones G (2018) Vitamin D toxicity- a clinical perspective. Frontiers in Endocrinology. Manuscript submitted 29 January 2018.

251. Jones G, Kaufmann M. Chapter 20: Vitamin D. In: Themed Issue on Metabolic Bone Diseases. (Eds: Drake M, Cremers S, Russell G, Bilezikian J). British J. Clinical Pharmacology. Invited chapter due July 1 2018.

**ABSTRACTS**

1. Jones, G and DeLuca, H.F. (1974). On the site of discrimination against D2 in chicks. Fed. Proc. **33**:680.

2. Jones, G., Baxter, L. and DeLuca, H.F. (1976). The biological activity of 1,25-dihydroxyvitamin D2 in chicks. Can. Fed. Biol. Sci. **19**:83.

3. Willetts, S.R., Houghton, S.E., Jones, G. and Pitt, G.A.J. (1976) An explanation of the paradoxical activities of α-retinol. Proc. Nutr. Soc. **35**:142A.

4. Kooh, S.W., Fraser, D. and Jones, G. (1977) Pathogenesis of rickets in chronic biliary cirrhosis. Clin. Res. **25**:682A.

5. Rosenthal, A.M., Jones, G., Kooh, S.W. and Fraser, D. (1978) Metabolism of 25-hydroxyvitamin D3 in the perfused rat kidney. In Endocrinology of Calcium and Metabolism. Eds. D.H. Copp and R.V. Talmage, Excerpta Medica, Amsterdam, p. 371.

6. Jones, G., Rosenthal, A. and Mazur, Y. (1978) Biosynthesis of 24(R),25-(OH)2D2 by a perfused rat kidney system. Third International Workshop on Calcified Tissues.

7. Rosenthal, A.M., Jones, G., Kooh, S.W. and Fraser, D. (1978) Metabolism of 25-OH-D3 by the isolated perfused rat kidney. Can. Fed. Biol. Soc. **21**:170.

8. Cifuentes, R.F., Duthie, D., Radde, I.C., Chance, G.W., Jones, G., Chabot, J., Sheepers, J. and Davis, D. (1978) 25-Hydroxyvitamin D levels in plasma of thriving very low birthweight infants on two intakes of vitamin D3. Can. Fed. Biol. Sci. **21**:46.

9. Hay, A.W.M. and Jones, G. (1979) Possible interference by 25,26-(OH)2D2 in the assay for 24,25-(OH)2D3. In Proc. of the 4th Workshop on Vitamin D, p. 58.

10. Murray, T.M., Kooh, S.W., Jones, G. and Fraser, D. (1979) Neonatal hypercalcemia due to vitamin D treatment of hypoparathyroidism during pregnancy. In Proc. of the 4th Workshop on Vitamin D, p. 80.

11. Cifuentes, R.F., Radde, I.C., Chance, G.W., Martin, D.J. and Jones, G. (1979) Effects of two oral doses of vitamin D3 in very low birthweight (VLBW) infants (< 1.3 kg). Pediatr. Res. **13**:512.

12. Jones, G., Vieth, R., Cifuentes, R.F. and Radde, I.C. (1980) Renal 25-hydroxyvitamin-D-hydroxylase and plasma metabolite concentrations in hypervitaminosis D. Program and Abstracts, American Society for Bone and Mineral Research, p. 36-A.

13. Shike, M., Sturtridge, W., Tam, C., Jones, G., Harrison, J., Wilson, D., Whitwell, J. and Jeejeebhoy, K. (1980) Bone disease and altered calcium metabolism associated with total parenteral nutrition. Program and Abstracts, American Society for Bone and Mineral Research, p. 17-A.

14. Tam, C.S., Jones, G. and Heersche, J.N.M. (1980) Effects of vitamin D depletion and repletion on the bone apposition rate in rats. Program and Abstracts, American Society for Bone and Mineral Research, p. 41-A.

15. Gray, T.K., McAdoo, T., Pool, D., Williams, M.E. and Jones, G. (1980) A radioimmunoassay for 1,25-dihydroxycholecalciferol. Program and Abstracts, Endocrine Society, p. 289, #857.

16. Reddy GS, Jones G, Fraser D (1980) Effects of acute metabolic acidosis on the conversion of 25-OH-D3 to 1,25-(OH)2D3 and 24,25-(OH)2D3 by the isolated perfused rat kidney. Program & Abstracts, Proc. VII Internat. Parathyroid Conference, #18.

17. Shike, M., Sturtridge, W.C., Harrison, J.E., Tam, C.S., Jones, G., Whitwell, J., Murray, T.M., Wilson, D.R. and Jeejeebhoy, KN (1980) Osteopenia associated with hypercalcemia & hypercalciuria induced by total parenteral nutrition: The role of vitamin D. Program & Abstracts, Proc. VII Internat. Parathyroid Conference, p. 7.

18. Harrison, J.E., Hitchman, A.J., Jones, G. and Tam, C.S. (1980) The effect in rats of nutritional phosphorus deficiency on the Linear Bone Apposition Rate: A measure of osteoblast activity in vivo. Proc. Program and Abstracts, Proc. VII Internat. Parathyroid Conference, #44.

19. Reddy, G.S., Jones, G., Kooh, S.W. and Fraser, D. (1981) Effect of chronic metabolism acidosis on the renal metabolism of 25-OH-D3 in the perfused rat kidney. Pediatr. Res. **15**:699.

20. Fraher LJ, Jones G, Clemens TL, Adami S, O'Riordan, J.L.H. (1981) Acta Endocrinologica, **97**, Supple. 243,8.

21. Jones, G., Harrison, J.E., Hitchman, T, Tam C, Heersche JNM. (1981) Is 1,25-(OH)2D3 the active form of vitamin D3 in bone formation? American Society for Bone and Mineral Research.

22. Reddy, G.S., Jones, G., Kooh, S.W., Fraser, D. and DeLuca, H.F. (1981) Stimulation of 24,25-(OH)2D3 synthesis in the perfused rat kidney. American Society for Bone and Mineral Research.

23. Reddy, G.S., Jones, G., Kooh, S.W., Fraser, D. and DeLuca, H.F. (1981) Stimulation of 24,25-(OH)2D3 synthesis in the perfused rat kidney. Can. Fed. Biol. Soc.

24. Harrison, J.E., Hitchman, A.J.W., Jones, G., Heersche, J.N.M. and Tam, C.S. (1981) The effect of phosphate deficiency on vitamin D and bone metabolism. Can. Soc. Clin. Invest.

25. Kooh, S.W., Rawlins, M., Vieth, R. and Jones, G. (1981) Metabolism of 25-Hydroxyvitamin D (25-OH-D) in the foetal kidney in the rat. Can. Soc. Clin. Invest.

26. Tam, C.S., Jones, G., Harrison, J.E. and Heersche, J.N.M. (1981) The role of 1,25-(OH)2D3 in bone formation. Royal College of Physicians and Surgeons of Canada.

27. Bouillon, R., Van Baelen, V., Tan, K.B., Jans, I., Van Merck, E., Uskokovic, M. and Jones, G. (1981) Calcified Tissue Interntl. (Suppl.): **33**:26, #194.

28. Fraher, L.J., Jones, G. and O'Riordan, J.L.H. (1982) Rapid sample preparation and evaluation of HPLC systems for isolation of vitamin D metabolites from serum. Fifth Workshop on Vitamin D, Abstracts, p. 289.

29. Heersche, J.N.M., Tam, C.S. and Jones, G. (1982) The regulatory role of vitamin D metabolites in bone formation. International Assoc. for Dental Research.

30. Fraser, D., Kooh, S.W., Reilly, B.J. and Jones, G. (1982) Failure of 1,25-(OH)2D3 alone to heal rickets due to vitamin D deficiency. Amer. Soc. Bone and Min. Research.

31. Tam, C.S., Heersche, J.N.M., Jones, G. and Murray, T. (1982) Regulation of bone formation by 24,25-(OH)2D3 in vivo and the interaction between 24,25-(OH)2D3 and PTH. Amer. Soc. Bone and Min. Res.

32. Wong, T.-Y., Jones, G., Reddy, G.S. and DeLuca, H.F. (1982) Metabolism of 24-difluoro, 25-hydroxyvitamin D3 in the isolated perfused rat kidney. Canadian Nephrology Soc.

33. Strasberg, P., Warren, I., Jones, G. and Lowden, J.A. (1982) HPLC galactosyl diglyceride as internal standard. Society for Complex Carbohydrates, Hershey, Penn.

34. Hodsman, A.B., Anderson, C., Jones, G. and Ghent, C.N. (1982) The relationship of hepatic osteodystrophy (OD) to calcium and vitamin D metabolism in early primary biliary cirrhosis (PBC). Clinical Disorders of Bone and Mineral Metabolism International Symposium.

35. Ghent, C.N., Anderson, C., Jones, G. and Hodsman, A.B. (1982) Cholestyramine, Calciuria, and bone disease in primary biliary cirrhosis (PBC). American Association for The Study of Liver Diseases.

36. Lee, S., Harrison, J., Jones, G., Fisher, M.M. and Heathcote, J. (1982) Calcium absorportion in asymptomatic primary biliary cirrhosis. American Association for The Study of Liver Diseases.

37. Jones, G., Kano, K., Kung, M. (1983) A novel renal pathway of 24,25-(OH)2D3 metabolism. Can. Fed. Biol. Soc.

38. Kung, M., Jones, G., Kooh, S.W. (1983) Effect of protein synthesis inhibitors on 25-hydroxyvitamin D metabolism in the isolated perfused rat kidney. Can. Fed. Biol. Soc.

39. Jones, G., Kung, M., Kano, K. (1983) 24,25-(OH)2Vitamin D3 metabolism in the perfused kidney from the D-replete rat. Amer. Soc. Bone and Min. Res.

40. Kano, K., Jones, G. (1983) Direct effects of T(3), T(4) and TSH on 25-hydroxyvitamin D3 metabolism by isolated perfused rat kidneys. Amer. Soc. Bone and Min. Res.

41. Tam, C.S. and Jones, G. (November 1983) VIII Intern. Conf. Calcium Regulating Hormones, Kobe, Japan.

42. Kano, K., Jones, G. (1984) Effects of Prednisolone on 25-hydroxyvitamin D3 metabolism in the rat. Amer. Soc. Bone and Min. Res.

43. Jones, G., Tam, C.S., Hitchman, A.J. and Harrison, J.E. (1984) The relationship between plasma vitamin D metabolites and bone apposition rates in phosphate deficient rats. Amer. Soc. Bone and Min. Res.

44. Hodsman, A. and Jones, G. (1984) Aluminum does not impair vitamin D3 metabolism or bone mineralization in D-deficient rats. Amer. Soc. Bone and Min. Res.

45. Petkovich, P.M., Heersche, J.N.M., Tinker, D.O. and Jones, G. (1984) Retinoic acid regulates 1α,25-dihydroxyvitamin D3 receptors in the ROS 17/2 rat osteosarcoma cell line. Amer. Soc. Bone and Min. Res.

46. Ghent, C.N., Jones, G., Hodsman, A.B. (1984) Acute responses to oral calcitriol in primary biliary cirrhosis. Canadian Assoc. Gastroenterology.

47. Petkovich, P.M., Heersche, J.N.M., Tinker, D.O. and Jones, G. (1984) Retinoic acid regulates 1,25-dihydroxyvitamin D3 receptors in the ROS 17/2 rat osteosarcoma cell line. Can. Soc. Clin. Invest.

48. Jones, G. (1985) Vitamin D Hydroxylation in the Perfused Kidney. Can. Fed. Biol. Soc.

49. Crilly, R.G., Toogood, J.H., Nadeau, J., Jones, G., and Wells, G.A. (1985) Inhated budesonide and calcium and phosphate metabolism. Amer. Soc. Bone Min. Res.

50. Petkovich, P.M., Heersche, J.N.M., Aubin, J.E. and Jones, G. (1985) Retinoic acid induced changes in 1,25-dihydroxyvitamin D3 receptor levels in tumor and non-tumor cells derived from rat bone. Amer. Soc. Bone and Min. Res. Abstract 321.

51. Bliziotes, M.M., de Grange, D.A., Jones, G. and Marx, S.J. (1985) Receptors in transformed lymphocytes from old world and new world primates demonstrate similar affinity for 1,25-(OH)2D3 and 1,25-(OH)2D2. Amer. Soc. Bone and Min. Res. Abstract 332.

52. Lohnes, D. and Jones, G. (1986) Role of retinoid binding proteins in retinoid induction of 1,25-(OH)2D3 receptor synthesis. Can. Fed. Biol. Soc.

53. O'Leary, T.J., Jones, G., Yip, A., Lohnes, D., Cohanim, M., and Yendt, E.R. (1986) The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. J. Bone and Min. Res. **1**, 173P.

54. Tenenhouse, H.S. and Jones, G. (1986) C-24 oxidation of 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in mouse kidney: effect of the X-linked Hyp mutation and 1,25-dihydroxyvitamin D3 treatment. J. Bone and Min. Res. **1**, 389P.

55. Jones, G., Edwards, N., Vriezen, D., Porteous, C., Trafford, D.J.H. and Makin, H.L.J. (1986) Side chain metabolism of dihydrotachysterol3 in vivo and in vitro in the rat. J. Bone and Mineral Res. **1**, 410 Abs.

56. Kano, K. and Jones, G. (1987) Direct effects of thyroid hormone, growth hormone and prednisolone on 25-hydroxyvitamin D3 metabolism in the isolated perfused rat kidney. Pediatric Nephrology **1**, C58.

57. Tenenhouse, H.S. and Jones, G. (1987) Effect of 1,25-dihydroxyvitamin D3 treatment and the X-linked Hyp mutation on C-24 oxidation of vitamin D3 in mouse kidney. J. Bone and Mineral Res. **2**, 438 Abs.

58. Jones, G. and Tenenhouse, H.S. (1987) Plasma 24,25-dihydroxyvitamin D3 levels not elevated in hypophosphatemic mice. J. Bone and Mineral Res. **2**, 465 Abs.

59. Lohnes, D., Jones, G. (1987) Target cell catabolism of 1,25-dihydroxyvitamin D3. J. Bone and Mineral Res. **2**, 304 Abs.

60. Tenenhouse, H.S. and Jones, G. (1987) Increased renal degradation of vitamin D3 metabolites in murine X-linked hypophosphatemic rickets. Canadian Pediatric Society, Montreal, July 4-8, 1987.

61. Porteous, C., Cunningham, J., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1987) Use of mass spectrometry in the identification of in vivo and in vitro metabolites of dihydrotachysterol in the rat. International Symposium on Applied Mass Spectrometry in the Life Sciences, Barcelona, Spain, Sept. 28-30, 1987.

62. Lohnes, D., Makin, G., Ray, R. and Jones, G. (1988) Calcitroic acid production from 1,25-dihydroxyvitamin D3 in perfused rat kidney and cultured bone cells. J. Bone Mineral Res. **3**, 202 Abs.

63. Miller, B.E., Chin, D.P. and Jones, G. (1988) Catabolism of 1,25-(OH)2D3 by primary cultures of human bone explant cells. J. Bone and Mineral Res. **3**, 194 Abs.

64. Porteous, C.E., Coldwell, R.D., Cunningham, J., Trafford, D.J.H., Makin, H.L.J. and Jones, G. (1988) What is the active metabolite of dihydrotachysterol? Studies on a non-renal dihydroxylated metabolite of dihydrotachysterol which is formed in vivo. J. Bone and Mineral Res. **3**, 195 Abs.

65. Simboli, M. and Jones, G. (1988) Regulation of renal 25-hydroxyvitamin D3 metabolism by dietary phosphate deprivation. Can. Fed. Biol. Soc., Quebec City, 664 Abs.

66. Strugnell, S., Tam, S.P., Deeley, R.G. and Jones, G. (1988) 25-hydroxylation of vitamin D by cultured human hepatoma cell lines. Can. Fed. Biol. Soc., Quebec City, 663 Abs.

67. Tomon, M., Tenenhouse, H.S. and Jones, G. (1989) Actinomycin D inhibits 1,25-dihydroxyvitamin D3-induced catabolism of vitamin D3 metabolites in mouse intestine. Endocrine Society, Seattle, USA, June 1989.

68. Lohnes, D. and Jones, G. (1989) Calcitroic acid production limits vitamin D receptor occupation in osteoblast derived cells. J. Bone Min. Res. **4** (Suppl) S261, Abstract 576.

69. Qaw, F.S., Makin, H.L.J. and Jones, G. (1989) Metabolism of 25-hydroxydihydro-tachysterol in UMR-106. J. Bone Min. Res. **4** (Suppl) S331, Abstract 854.

70. Schroeder, N., Coldwell, R.D., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1989) Further studies on the polar metabolites of dihydrotachysterol formed in vivo in the rat. J. Bone Min. Res. **4** (Suppl) S300, Abstr 730.

71. Strugnell, S., Calverley, M. and Jones, G. (1989) C24-substitution of cyclopropane-ring-containing vitamin D3 analog in a new HEP-3B liver cell model. J. Bone Min. Res. **4** (Suppl) S385, Abstract 1072.

72. Tenenhouse, H.S., Byford, V. and Jones, G. (1989) Abnormal regulation of renal vitamin D metabolism in response to dietary phosphate in X-linked Hyp mice. J. Bone Min. Res. **4** (Suppl) S266, Abstract 595.

73. Yendt, E.R., Cohanim, M., Jarzylo, S., Jones, G. and Rosenberg, G. (1989) Creatine clearance and urinary hydroxyproline are related to skeletal mass in normal women. J. Bone Min. Res. **4** (Suppl) S180, Abstract 252.

74. Yendt, E.R., Cohanim, M., Jarzylo, S., Jones, G. and Rosenberg, G. (1989) Reduced glomerular filtration and a renal tubular calcium leak in women with primary osteoporosis. J Bone Min Res **4** (Suppl) S181, Abstract 253.

75. Guo, Y-D., Jones, G. (1990) Retinoic acid stimulates vitamin D receptor mRNA levels in the rat osteosarcoma UMR-106. Can. Fed. Biol. Soc. Halifax, Abstract 067.

76. Li, Z.M., Jones, G. and Anastassiades, T. (1990) The regulation of proteoglycans and bone sialoprotein synthesis by 1,25-dihydroxyvitamin D3 in rat osteosarcoma cell lines UMR-106 and ROS 17/2. Can. Fed. Biol. Soc. Abstract 354.

77. Chopra, R.K., Lohnes, D., Jones, G. and Anastassiades, T. (1990) Purification and further characterization of the major anionic glycoconjugate secreted by UMR-106 cells. Can. Fed. Biol. Soc. Abstract 356.

78. Guo, Y-D., Whitfield, G.K., Komm, B.S., Haussler, M.R. and Jones, G. (1990) Retinoic acid stimulates vitamin D receptor mRNA and retinoic acid receptor-β mRNA levels in the rat osteosarcoma UMR-106. J. Bone & Min. Research 5(Suppl):S158, Abstract 339.

79. Qaw, F., Calverley, M.J., Schroeder, N., Makin, H.L.J., Trafford, D.J.H. and Jones, G. (1990) 25-Hydroxylation of synthetic 1-hydroxydihydrotachysterols: Comparison with in vivo metabolites in the rat. J. Bone & Min. Research 5(Suppl):S200, Abstract 505.

80. Strugnell, S., Calverley, M.J. and Jones, G. (1990) Metabolism of 24-oxo-1α-hydroxyvitamin D3 by cultured liver cells. J. Bone & Min. Research 5(Suppl):S200, Abstract 506.

81. Li, Z-M., Guo, Y-D., Anastassiades, T. and Jones, G. (1991) Retinoic acid suppresses the proteoglycan level in the rat osteosarcoma cell line ROS 17/2. Presented to the Canadian Federation of Biological Sciences, Kingston, June.

82. Qaw, F. and Jones, G. (1991) Search for the active form of the calcemic drug, dihydrotachysterol. Presented to the Canadian Federation of Biological Sciences, Kingston, June.

83. Strugnell, S., Qaw, F. and Jones, G. (1991) Stereospecificity of human hepatic vitamin D 25-hydroxylases. Presented to the Canadian Federation of Biological Sciences, Kingston, June.

84. Qaw, F., Schroeder, N.J., Calverley, M.J., Trafford, D.J.H., Makin, H.L.J. and Jones, G. (1991) Understanding dihydrotachysterol metabolism: Light at the end of the tunnel. Presented to the Eighth Workshop on Vitamin D, Paris, July 5-10, 1991.

85. Guo, Y-D., Strugnell, S. and Jones, G. (1991) Identification of a human liver mitochondrial cytochrome P-450 cDNA corresponding to the vitamin D3-25-hydroxylase. J. Bone and Mineral Research **6**, S120, Abstract 149.

86. Jones, G., Haussler, C., Meyer, J., Komm, B.S. and Haussler, M.R. (1991) A rapid, non-chromatographic assay for assessing catabolism of calcitriol *in vitro*. J. Bone and Mineral Research **6**, S123, Abstract 163.

87. Meyer, J., Galligan, M., Jones, G., Komm, B.S. and Haussler, M.R. (1991) 1,25-(OH)2D3-Dependent regulation of calbindin-D28K mRNA apparently requires the synthesis of an uncharacterized protein in chick duodenal organ culture. J. Bone and Mineral Research **6**, S185, Abstract 406.

88. Qaw, F., Calverley, M.J., Schroeder, N.J., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1991) Metabolism of 25-hydroxydihydrotachysterol (25-OH-DHT) *in vivo* in the rat: Non-renal formation of 1α- and 1β-hydroxylated metabolites. J. Bone and Mineral Research **6**, S121, Abstract 154.

89. Jones, G. (1991) Further metabolism of 1,25-dihydroxyvitamin D3 in target tissues. Presented to the First International Congress on Vitamins and Biofactors in Life Science, Kobe, Japan, September 16-20, 1991.

90. Schroeder, N., Qaw, F., Calverley, M.J., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1992) Use of dihydrotachysterol, a synthetic vitamin D analogue, has demonstrated that 1β-Hydroxylation occurs in vivo in the rat. Ninth International Congress of Endocrinology, Paris, France, September 1992.

91. Qaw, F., Schroeder, N.J., Calverley, M.J., Maestro, M., Mourino, A., Trafford, D.J.H., Makin, H.L.J. and Jones, G. (1992) In vitro synthesis of 1,25-dihydroxydihydrotachysterol in the myelomonocytic cell line, HD-11. J. Bone Mineral Res **7**, S161, Abstract 274.

92. Strugnell, S., Moriarty, R.M., Gilardi, R., Knutson, J.C., Bishop, C.W. and Jones, G. (1992) Stereochemistry of human liver cell-derived 1α,24(OH)2D2. J. Bone Mineral Res **7**, S161, Abstract 273.

93. Strugnell, S., Guo, Y.-D., Tremblay, E., Makin, H.L.J. and Jones, G. (1992) Transfected human cytochrome P-450 hydroxylates vitamin D analogs at distinct side chain positions. J. Bone Mineral Res **7**, S161, Abstract 275.

94. Dilworth, F.J., Calverley, M., Makin, H. and Jones, G. (1993) Increased biological activity of 20-epi-1,25-(OH)2D3 is due to altered protein binding and reduced catabolism. J. Bone Mineral Res **8**, S170, Abstract 213.

95. Masuda, S., Strugnell, S., Calverley, M.J., Makin, H.L.J., Kremer, R. and Jones, G. (1993) Metabolism of calcipotriol in cultured human keratinocyte cell lines. J. Bone Mineral Res **8**, S211, Abstract 379.

96. Schroeder, N.J., Trafford, D.J.H., Cunningham, J., Jones, G. and Makin, H.L.J. (1993) In vivo dihydrotachysterol2 metabolism in normal man: formation of 1α,25- and 1β,25-dihydroxylated metabolites and effect on endogenous parathyroid hormone and 1α,25-dihydroxyvitamin D concentration. J. Bone Mineral Res **8**, S217, Abstract 403.

97. Strugnell, S., Dilworth, J., Guo, Y.D., Roberts, E., Tam, S.P. and Jones, G. (1993) Retinoic acid increases 25-hydroxylase activity in cultured human liver cell lines. J. Bone Mineral Res **8**, S211, Abstract 380.

98. Jones, G. (1993) Metabolism of 1,25-dihydroxyvitamin D3 and its analogs. The International Bone Forum II, Yokohama, Japan, November 4 & 5,1993. **(Invited Lecture)**

99. Green, A., Dilworth, J., Calverley, M.C., Makin, H.L.J. and Jones, G. (1993) Studies of the specificity of the enzymes involved in the side chain metabolism of 1,25-dihydroxyvitamin D3: Mass spectrometry of metabolites of 1,25-dihydroxy-24-homo-vitamin D3 (MC1127). J Endocrinol **139**, P-7(Abs).

100. Dilworth, F.J., Strugnell, S., Guo, Y.-D., Calverley, M.J., Makin, H.L.J. and Jones, G. (1994) Site and rate of hydroxylation of 1α-OH-D3 analogs by CYP27 not altered by increasing length or changing orientation of vitamin D3 side chain. Ninth Workshop on Vitamin D, Orlando, Florida, June 1994.

**(Young Investigator Award for graduate student FJ Dilworth)**

101. Jones, G. (1994) Target cell metabolism of vitamin D and its analogs. Ninth Workshop on Vitamin D, Orlando, Florida, June 1994. **(Invited Lecture)**

102. Jones, G., Byford, V., Kremer, R., Makin, H.L.J., Knutson, J.C. and Bishop, C.W. (1994) Novel cleavage of vitamin D2 side chain during catabolism by keratinocyte cell line. Ninth Workshop on Vitamin D, Orlando, Florida, June 1994.

103. Masuda, S., Byford, V., Makin, H.L.J., Kremer, R., Okano, T., Kobayashi, T., Kubodera, N., Nishii, Y. and Jones, G. (1994) 22-Oxacalcitriol is metabolized to C21 side-chain cleaved products in both liver and target cells. Ninth Workshop on Vitamin D, Orlando, Florida, June 1994.

104. Guo, Y-D., Jones, G. (1994) Gene promoter for human liver vitamin D3-25-hydroxylase (CYP27) lacks a classical VDRE but contains silencer sequence. J. Bone Mineral Res **9:** S289, Abstract B237.

105. Masuda, S., Makin, H.L.J., Kremer, R., Okano, T., Kobayashi, T., Sato, K., Nishii, Y., and Jones, G. (1994) Metabolism of 2β-(3-hydroxypropoxy)-1α,25-dihydroxyvitamin D3 (ED-71) in cultured cell lines. J. Bone Mineral Res **9:** S289, Abstract B238.

106. Dilworth, F.J., Scott, I., Green, A., Makin, H.L.J., Calverley, M.J., and Jones, G. (1994) Hydroxylation site of 23- and 24-hydroxylases determined by distance from vitamin D ring structure. J. Bone Mineral Res **9:** S289, Abstract B239.

107. Jones, G., Byford, J., Strugnell, S., Kremer, R., Makin, H.L.J., Knutson, J.C., and Bishop, C.W. (1994) 1α,24(S)-dihydroxyvitamin D2: Biologically active analog with unique metabolic properties. J. Bone Mineral Res **9:** S344, Abstract B461.

108. Schroeder, N.J., Qaw, F., Calverley, M.J., Hoyer, T., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1994) Mass spectral evidence of in vitro 10-hydroxylation of 25-hydroxy-dihydrotachysterol by a myelomonocytic leukaemic cell line, HD-11. J. Endocrinol **143**, suppl, P33. Presented at 185th Meeting of the Society for Endocrinology, London UK, November 23-25th, 1994.

109. Schroeder, N.J., Trafford, D.J.H., Jones, G. and Makin, H.L.J. (1995) Studies on the differential binding of dihydrotachysterol metabolites to the chick gut and calf thymus vitamin D-receptor proteins (VDR). Presented to the 14th Joint Meeting of the British Endocrine Societies held at University of Warwick, Warwick, U.K., March 27-30, 1995.

110. Kissmeyer, A.-M., Shankar, V.N., Jones, G., and Makin, H.L.J. (1995) The in vitro and in vivo metabolism of EB1089. Presented to the Bone and Tooth Society "Symposium on Vitamin D Analogues" at the University of Warwick, Warwick, U.K., March 27, 1995.

111. Shankar, V.N., Makin, H.L.J., Schroeder, N.J., Trafford, D.J.H., Kissmeyer, A.-M., Binderup, E., Calverley, M.J. and Jones, G. (1995) Metabolism of the antiproliferative vitamin D analogue, EB1089, in a cultured human keratinocyte model. Presented to the Bone and Tooth Society "Symposium on Vitamin D Analogues" at the University of Warwick, Warwick, U.K., March 27, 1995.

112. Mawer, E.B., Davies, M., Still, P.E., Jones, G., Knutson, J.C., and Bishop, C.W. (1995) 1,24(S)-Dihydroxyvitamin D2 a biologically active analogue of vitamin D, is a naturally occurring metabolite in humans. Presented to the Bone and Tooth Society "Symposium on Vitamin D Analogues" at the University of Warwick, Warwick, U.K., March 27, 1995.

113. Makin, H.L.J., Trafford, D.J.H., Calverley, M.J., and Jones, G. (1995) Gas chromatography-mass spectrometry as a means of determining the structures of metabolites formed in vitro by cultured cell lines incubated with chemical analogues of vitamin D. Presented to the Bone and Tooth Society "Symposium on Vitamin D Analogues" at the University of Warwick, Warwick, U.K., March 27, 1995.

114. Kissmeyer, A.-M., Binderup, E., Shankar, V.N., Jones, G., and Makin, H.L.J.(1995) The in vitro and in vivo metabolism of EB1089. Presented to The International Society for the Study of Xenobiotics Meeting at Seattle, Washington, USA, August 27-31, 1995.

115. Demers, C., Lapointe, R., Valiquette, L., Guo, Y.-D., Jones, G and Gascon-Barré, M.(1995). Human liver expression CYP27, a gene encoding a cytochrome P450 active in the 25-hydroxylation of vitaminD3. J Bone Mineral Res **10:** S493, Abs T556.

116. Dilworth, F.J., Scott, I., Calverley, M.J., Makin H.L.J., and Jones, G. (1995) Enzymes of side chain oxidation pathway not affected by addition of methyl groups to end of the vitamin D3 side chain. J Bone Min Res **10:** S388, Abs M546.

117. Shankar, V.N., Makin H.L.J., Schroeder, N.J., Trafford, D.J.H., Kissmeyer, A.-M., Binderup, E., Calverley, M.J. and Jones, G. (1995). Metabolism of vitamin D analogs containing side chain double bonds: conjugated system of EB1089 blocks 24-hydroxylation. J Bone Min Res **10:** S389, Abs M548.

118. Davies M.,Mawer EB, Still PE, Selby PL, Jones G, Knutson JC, Bishop CW (1995) Synthesis of 1,24(S)-Dihydroxyvitamin D2 in humans with disorders of mineral metabolism. J Bone Min Res **10:** S289, Abs S555.

119. Jones G, Strugnell S, Guo Y-D, Lohnes D, Dilworth FJ, and Makin HLJ (1995). Retinoic acid increases activity of vitamin D side chain hydroxylases in liver and bone cell lines. Retinoids 95, Oct 8-11, Sophia-Antipolis, France. Abstract #122, p79.

120. Jones G (1996) Metabolism of vitamin D analogues. 3rd International Calcipotriol Symposium, Munich, Germany, March 23 1996. **(Invited lecture)**

121. Dilworth FJ, Calverley MJ, Kissmeyer A-M, Binderup E, Makin HLJ & Jones G (1996) KH1060, a potent vitamin D analog is degraded in cultured keratinocytes viaseveral different pathways. J Bone Mineral Res **11:**S424, Abs T500.

122. Prosser DE, Dakin KA, Donini OAT, Weaver DF, Jia Z and Jones G (1996) A three dimensional model of the cytochrome P450, CYP27 and its vitamin D-binding site. J Bone Mineral Res **11:**S313, Abs M525.

123. Masuda S, Okano T, Kamao M, Kremer R, Jones G and Kobayashi T (1996) Different metabolism of 1,25-dihydroxyvitamin D3 in target cells. J Bone Mineral Res **11:**S420, AbsT484.

124. Makin HLJ, Jones G, Trafford DJH, Schroeder NJ and Calverley MJ (1996) Interpretation of mass spectra of *in vitro* metabolites of vitamin D and its chemical analogs. Amer Soc Mass Spectrometry.

1. Shankar, V.N., Dilworth F.J., Makin H.L.J., Schroeder, N.J., Trafford, D.J.H., Kissmeyer, A.-M., Calverley, M.J. Binderup, E. and Jones, G. (1996).

In Vitro Metabolism of EB1089 to 26- and 26a-hydroxylated products: conjugated system of side chain directs hydroxylation to distal carbons. Fourth Annual Brown University Symposium on Vitamin D. Providence RI, September 12-14 1996, Abs 8.

1. Jones G Metabolism of vitamin D and its analogs. Fourth Annual Brown University Symposium on Vitamin D, Providence RI, September 12-14, 1996. **(Invited Lecture)**

127. Jones G. Recent developments in the metabolism of clinically relevant vitamin D analogs. International Workshop on the Vitamin D Cascade, Vienna, Austria, May 22-23, 1997. **(Invited Lecture)**

128. Jones G. Metabolism of vitamin D and its analogs. Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29 1997. **(Invited Lecture)**

129. Dilworth FJ, Chithalen JV, Williams GW, Calverley MJ, Kissmeyer A-M, Binderup E, Makin HLJ and Jones G (1997) KH1060 is metabolized in cultured keratinocyte and hepatocyte cell lines via multiple pathways to biologically active products, Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29 1997, abstract.

130. Jones G, Byford V, Makin HLJ, Knutson JC and Bishop CW (1997) 1α-Hydroxyvitamin D4 and its epimer: Analogs with altered hepatic cell metabolism giving metabolites with improved DBP and decreased VDR affinity. Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29 1997, abstract.

131. Kissmeyer A-M, Binderup E, Binderup L, Mork-Hansen C, Rastrup-Andersen N, Logsted-Nielsen J, Makin HLJ, Schroeder NJ, Shankar VN and Jones G (1997) In vivo and in vitro metabolism of the vitamin D analog EB1089. Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29 1997, abstract.

132. Shankar VN, Schroeder NJ, Makin HLJ, Wiesinger H, Neef G, Steinmeyer A and Jones G (1997) Metabolism of 20-methyl substituted vitamin D analogs by cultured human cells : 20-methyl group apparently reduces 23-hydroxylation of the side-chain. Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29 1997, abstract.

133. Jones G.(1997) Mechanisms of vitamin D analog action. Vitamin D Brainstorming Workshop, Whistler, Canada. July 31-August 1 1997. **(Invited Lecture)**

134. Jones G, Byford V, Makin HLJ, Knutson JC and Bishop CW (1997) 1α-hydroxyvitamin D4, 24-epi-1α-hydroxyvitamin D4 and 1α-hydroxy-22-vitamin D3 : analogs to probe the differences in hepatic cell metabolism of vitamins D2 and D3. J Bone Mineral Res 12:S451 (Abs S395).

135. Van Den Bemd GJCM, Dilworth FJ, Williams GW, Pols HAP, Jones G and van Leeuwen JPTM (1997) Metabolites of the 1,25-dihydroxyvitamin D3 analog KH1060 induce similar conformational changes as KH1060 itself. (1997) J Bone Mineral Res 12: S453 (Abs S401).

136. Guo Y-D, White J, Jones B, Dilworth J, Petkovich M and Jones G (1997) Human retinoic acid-inducible cytochrome P450 (hP450RAI): retinoic acid metabolizing protein plays an important role in attenuation of retinoic acid signal. J Bone Mineral Res 12: S456 (Abs S415).

137. Schroeder NJ, Makin HLJ, Dilworth FJ, Jones G, Kissmeyer A-M (1998) Characterization of in vitro metabolites of KH1060, a potent calcitriol analog, by GC-MS. Abstract for the 46th Conference on Mass Spectrometry & Allied Topics, Orlando, Florida, USA May31-June 4 1998

138. Schroeder NJ, Makin HLJ, Vince J, Masuda S, Dilworth FJ, Jones G (1998) Metabolism of 22-oxa chemical analogs of calcitriol : mass spectrometry of side-chain truncated metabolites formed in vitro. Abstract for the 46th Conference on Mass Spectrometry & Allied Topics, Orlando, Florida, USA May 31-June 4 1998

139. Jones G (1998) Recommended intake of vitamin D. In: Joint FAO/WHO Expert Consultation on Human Vitamin and Mineral requirements. Bangkok, Thailand 21-30 September **(Invited Lecture)**.

140. Jones G (1998) Differences in the metabolism of D hormones. In: New Expectations for D-Hormone Therapy. A University of Wisconsin mini-symposium. American Society of Nephrology, Philadelphia PA. October 26 1998. **(Invited Lecture)**.

141. Moore B, Makin HLJ, Schroeder NJ, Calverley MJ, Jones G (1998) Metabolism of Double Side-Chain Calcitriol Analogs by a human keratinocyte cell line. Bone 23 :S451, F168 (abstract)

142. Petkovich M, Ramshaw H, Zhang A, Cook R, Byford V, White J, Jones G. (1998). Expression of extra-renal 25-OH-D-1α-hydroxylase in human non-small cell lung carcinoma lines from hypercalcemic patients. Bone 23 :S262, T255 (abstract)

1. Kovacs K, Yendt E, Lane J, Jones G (1998) Comparison of serum 25-hydroxyvitamin D responses to ingested vitamin D2 in young versus elderly volunteers. Bone 23 :S642, SA494 (abstract).
2. Prosser D, Guo Y-D and Jones G (1999) Mutations of the mitochondrial vitamin D3-25-hydroxylase, CYP27, cause changes in the ratio of 25- and 27-hydroxylated products. J Bone Mineral Res 14:S548, Su468 (abstract).
3. Jones G, Byford V, Guo Y-D, Knutson JC, Bishop C, Schroeder N, Makin HLJ (1999) Cultured human keratinocytes both activate & catabolize 1α-hydroxyvitamin D2 analogs. J Bone Mineral Res 14:S305,F475, abs.
4. Jones G (1999) The mechanism of action of vitamin D analogs **(Invited lecture).**

8th International Conference on Differentiation Therapy. Montreal, PQ October 3-6 1999.

1. Jones G (2000) An update on Vitamin D metabolism (**Invited Lecture**) as part of Eleventh Workshop on Vitamin D, Nashville, Tennessee, USA, May 27-June 1 2000.
2. Jones G (2000) Molecular Actions of Vitamin D and its Analogs **(Invited lecture)** as part of Modern Trends in Skin Pharmacology, Athens, Greece, June 8-11, 2000.
3. Demers C, Ghrab O, Theodoropoulos, Lapointe R, Jones G, Valiquette L, Menard D and Gascon-Barre M (2000) Expression of CYP27A, a gene encoding a vitamin D-25 hydroxylase in human liver and kidney, Endocrine Society 82nd Annual Meeting, Toronto, Ontario, Canada, June 21-24.
4. Jones G, Byford V, Arabian A, St-Arnaud R (2000).Altered Pharmacokinetics of 1α,25-(OH)2D3 in Blood and Tissues of the CYP24-null Mouse. **(Selected Oral program)** 22nd Annual Meeting of the American Society of Bone and Mineral Research, J Bone Mineral Research 15: abstract 1246, S199
5. Jones G, Byford V, Makin HLJ, Knutson JC, Strugnell S, Bishop CW (2000).New Vitamin D Prodrug Metabolized in Liver and Target Cells to Biologically Active Molecules. 22nd Annual Meeting of the American Society of Bone and Mineral Research, J Bone Mineral Research 15: abstract M506, S575.
6. Jones G, Byford V, Sakai Y, Demay M (2000) Dramatic Reduction of 1,25-(OH)2D3 Catabolism in Keratinocytes from VDR-null Mice **(Selected Oral program)** 22nd Annual Meeting of the American Society of Bone and Mineral Research, J Bone Mineral Research **15**: abstract 1172, S181
7. Jones G, Byford V, Moore B, Logsted-Nielsen J, Calverley MJ, Hansen K, Kissmeyer A-M (2000) A Novel Aromatic Vitamin D Analog is Rapidly Metabolized in Cultured Cell Lines In Vitro. 22nd Annual Meeting of the American Society of Bone and Mineral Research, J Bone Mineral Research **15**: abstract M507, S576.
8. Prosser DE, Guo Y-D, Jia Z, Jones G.(2000) Mutations at Ser404 and Val515 Drastically Alter the Ratio of In Vitro 25- and 27-Hydroxylation Products of 1α-OH-D3 Formed by CYP27. 22nd Annual Meeting of the American Society of Bone and Mineral Research, J Bone Mineral Research **15**: abstract SA519, S331.
9. Masuda S, Bates J, Prosser DE, Guo Y-D, Jones G (2001) LC-MS based substrate specificity studies of wildtype and mutagenized versions of vitamin D 25-hydroxylase CYP27A1. 23nd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix AZ held October 12-16 2001. J Bone Mineral Research **16**: abstract SU522, S432.
10. Kaufmann M, Masuda S, Jones G (2001) LC-MS based enzyme kinetic analysis of CYP24 confirms that 1α,25-(OH)2D3 is a physiologically relevant substrate. 23nd Annual Meeting of the American Society of Bone and Mineral Research, Phoenix AZ held October 12-16 2001. J Bone Mineral Research **16**: abstract SA529, S313.
11. Jones G (2002) **Invited speaker** at “Symposium on vitamin D analogs in the prevention and therapy of cancer" held in Homburg, Saar, Germany, May3-4, 2002. Organizer: Dr J. Reichrath, Saarland University Hospital.
12. Kaufmann M, Masuda S, Chithalen J, Petkovich M and Jones G (2002). LC-MS based studies of CYP24 and CYP26A emphasize the similarities of the catabolism of 1α,25-(OH)2D3 and all-*trans* retinoic acid. “DeLuca Symposium on Vitamin D”, Taos, New Mexico, June 15-19 2002 **(Invited speaker)**. (Postponed from Oct 10-12, 2001) Organiser: Dr John Omdahl, University of New Mexico, Alberquerque, NM, USA.

159. Kaufmann M, Masuda S and Jones G (2002) LC-MS-based metabolic studies of 1α,25-(OH)2D3 and 20-methyl-1α,25-(OH)2D3 reveals reduced clearance through CYP24-catalyzed C24-oxidation. 24th Annual Meeting of the American Society of Bone and Mineral Research, held in San Antonio TX September 20-24 2002. J Bone Mineral Research **17**: S394, abstract SU452.

160. Masuda, S, Arabian, A, McCaig J,Kaufmann M, Strugnell SA, Knutson JC,  St-Arnaud R and Jones G.(2002) CYP24-Null Keratinocytes Demonstrate that CYP24 Is Responsible for Activation and Inactivation of 1α(OH)D2. 24th Annual Meeting of the American Society of Bone and Mineral Research, held in San Antonio TX September 20-24 2002. J Bone Mineral Research **17**: S396, abstract SU459.

161. Chuang SS, Zhang A, Jones G, Kahraman M, Posner GH, and Korczak B (2003) CYP24 Inhibitor CTA091 results in the enhancement of calcitriol’s effect on keratinocyte cell proliferation. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract Su30, P23.

162. Makin HLJ, Masuda S, and Jones G (2003) Mass Spectrometry for quantitation and identification of vitamin D, analogs and metabolites. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract Su52, P34.

163. Chuang SS, Zhang A, Jones G, Posner GH, and Korczak B (2003) A non-calcemic vitamin D analog selectively inhibits CYP24 activity and cell proliferation. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract Mo30, P89.

164. Carter GD, Gunter E, Jones J, Jones G, Makin HLJ, and Sufi S (2003) Measurement of vitamin D metabolites: an international perspective on techniques and clinical interpretation. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract Mo48, P98.

165. Masuda S, Byford V, Knutson JC, Strugnell S, Arabian A, St-Arnaud R and Jones G (2003) Insights into vitamin D metabolism from studies of the C24-null mouse. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract We55, P152.

166. Jones G, Byford V, Kaufmann M, Gao M, Arabian A and St-Arnaud R (2003) CYP24 Overexpression and knockout systems reveal the different roles of CYP24 in 25-OH-D3 and 1α,25-(OH)2D3 metabolism. Proceedings of the 12th Workshop on Vitamin D, Maastricht, Netherlands, July 6-July 10, 2003 abstract We51, P180.

167. Helvig C, Wisniewski J, Ramshaw H, Amad M, Gao M, Chuang S, Taimi M, Jones G, Petkovich M, White JA and Korczak B (2003) CYP2U1, a thymus and cerebellum expressed cytochrome P450 converts arachidonic acid into bioactive derivatives 19- and 20-HETE. 13th International Conference on Cytochromes P450 Biochemistry, Biophysics and Drug Metabolism, Prague, Czech Republic, June 29 - July 3, 2003

168. Kaufmann M, Masuda S, Byford V, St-Arnaud R, Arabian A and Jones G (2003) Establishing the role of CYP24 in the metabolism of natural vitamin D compounds and their synthetic analogs. American Soc Bone & Mineral Research, Minneapolis MN September 19-23, 2003. abstract

169. Jones G (2003) 11th Annual Providence Symposium on Vitamin D -2003 -Vitamin D and Drug Development, Providence Rhode Island, USA, September 24-26, 2003 **(Invited speaker)**.

170. Jones G (2003) The essential role of vitamin D in “The Influence of the KDOQI Guidelines on Chronic Kidney Disease Treatment Patterns”, Chicago, IL, USA. December 12-13 2003 (**Invited Speaker)**

171. Jones G (2004) The essential roles of vitamin D in the management of Chronic Kidney Disease in Symposium on “ Treating Stage 3 and 4 CKD & the K/DOQI Bone Metabolism Guidelines” May 1, 2004 Chicago IL, USA as part of National Kidney Foundation 2004 Clinical Meetings (April 28-May 2, 2004). (**Invited Speaker**)

172. Jones G (2004) “An overview of vitamin D3-25-hydroxylase and the potential cytochrome P450s involved.” in “Twelfth Annual Providence Symposium on Vitamin D” Sept 29-30 2004. Providence, Rhode Island, USA. (**Invited Speaker & Career Achievement Award**)

173. Jones G (2004) The essential roles of vitamin D in the management of Chronic Kidney Disease in Symposium on “ Treating Stage 3 and 4 CKD and the K/DOQI Bone Metabolism Guidelines” October 29, 2004 St Louis, MI, USA as part of American Society for Nephrology 2004 Meetings (Oct 27-Nov.1, 2004). (**Invited Speaker**).

174. Jones G (2005) **Invited Speaker** at “Stephen Z Fadem Symposium of the National Kidney Foundation of Southeast Texas” Houston, Texas USA on February 18 2005.

175. Jones G (2005) **Invited Speaker** at National Kidney Foundation Symposium “Undiagnosed secondary hyperparathyroidism in early chronic kidney disease: the essential role of D hormone and a new treatment paradigm to manage SHPT in early CKD”, Washington DC May 6 2005. Organizers: National Kidney Foundation.

176. Jones G (2005) **Invited speaker** at “2nd Symposium on vitamin D analogs in the prevention and therapy of cancer", Lubeck, Germany, May 7-8, 2005. Organizer: Dr Jorg Reichrath, Saarland University Hospital & Presented abstract: Jones G, Byford V, Masuda S, Ibrahim G, Kaufmann M, Knutson J, Strugnell S and Mehta R. Hepatic Activation and Inactivation of Clinically-relevant vitamin D analogs and prodrugs” Anticancer Research.

177. Jones G (2005) **Invited Speaker** at Florida Society of Nephrology 37th Annual Meeting “Managing kidney patients with metabolic bone disease”. Fort Lauderdale FL. September 16-18 2005. Organizers: Florida Society of Nephrology.

178. Masuda S, Prosser DE, Kaufmann M, Guo Y-D, Thede G, Yam K, Jones G (2006) Modelling and mutagenesis studies of CYP24A1 implicate important residues in substrate recognition and catalysis. “Thirteenth Workshop on Vitamin D”, Victoria BC, Canada. April 8-12 2006. Abstract Book: Sunday Poster 61, Page 103.

1. Kaufmann M, Byford V, Jones G (2006) Vitamin D-binding Protein helps mediate the differential catabolism of 1α,25-(OH)2D3 and 25-OH-D3 by CYP24 in kidney and vitamin D target cells. “Thirteenth Workshop on Vitamin D”, Victoria BC, Canada. April 8-12 2006. Abstract Book: Saturday Poster 61, Page 41.
2. Prosser D, Kaufmann M, O’Leary B, Jones G (2006) A single amino acid substitution converts human CYP24 from a 24-hydroxylase into a 23-hydroxylase which synthesizes the VDR antagonist 1,25-(OH)2D3-26,23-lactone. ASBMR-sponsored meeting “Contemporary Diagnosis and Treatment of Vitamin D-related Disorders”. Washington DC USA December 4-5 2006. Poster.
3. Jones, G. (2006**) Invited Speaker:** “Measurement of 25-OH-D (RIA, HPLC, LC-MS/MS)”, ASBMR-sponsored meeting “Contemporary Diagnosis and Treatment of Vitamin D-related Disorders” held in Washington DC, USA. December 4-5 2006.
4. Jones, G. (2007) **Invited Speaker:** “The Essential Role of Vitamin D in the Pathogenesis of Secondary Hyperparathyroidism: The Importance of Classical and Non Classical Actions of Calcitriol”. University of Texas-Houston Medical Center, Houston TX, USA. April 17 2007.

183. Prosser D, Kaufmann M, O’Leary B, Byford V, Jones G (2007) **Invited Speaker: “**A single amino acid substitution the human CYP24A1 from a 25-OH-D3-24-hydroxylase into a 25-OH-D3-23-hydroxylase mimicking the natural orthologue found in the opossum. Fourteenth Annual Brown University Symposium on Vitamin D, Providence, Rhode Island, USA. June 22-23, 2007.

184. Jones G (2007) **Invited Speaker:** “Pharmacokinetics of Vitamin D Toxicity”, National Institutes of Health (NIH) Conference, “Vitamin D and Health in the 21st Century–An Update” Bethesda MD USA. September 5-6 2007.

185. Jones G (2007) **Invited Speaker**: “The Classical and Non-Classical Actions of Calcitriol Analogs on CKD Patients” in “Mini-Symposium on Vitamin D Health Benefits”**.** Annual Meeting of the National Kidney Foundation, San Francisco, USA, November 4 2007.

186. Jones G (2007) **Invited Speaker**: “An Expanding Role for Vitamin D in Chronic Kidney Disease: Classical and Non Classical Actions of Calcitriol”, Cleveland Clinic Nephrology & Hypertension Grand Rounds, Cleveland OH, USA. November 30 2007.

187. Jones G (2007) **Invited Speaker**: “Role for Vitamin D and its Analogs in Chronic Kidney Disease & Prostate Cancer Prevention”, Brookdale Hospital Urology Grand Rounds, New York, NY, USA. December 19 2007.

188. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Chronic Kidney Disease: Classical & Non Classical Actions of Calcitriol”, Vanderbilt University Medical Centre, Nephrology & Hypertension Grand Rounds, Nashville TN, USA. January 10 2008.

189. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Human Health: Classical and Non Classical Actions of Calcitriol”, Stony Brook Medical Center Medical Grand Rounds, Stony Brook NY, USA. January 16 2008.

190. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Chronic Kidney Disease: Classical and Non Classical Actions of Calcitriol”, New York University, Medical Grand Rounds, New York City, NY, USA. April 7 2008.

191. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Human Health: New Insights into an Old Story”, 2008 Utah Dietetic Association Annual Meeting, Layton UT, USA. April 17 2008.

192. Jones G (2008) **Invited Speaker:** at “3nd Symposium on Vitamin D Analogs in Cancer Prevention and Therapy" at Krefelder Hof in Krefeld, Germany. May 17-18, 2008. Organizer: Dr Jorg Reichrath, Saarland University Hospital.

193. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Chronic Kidney Disease: Classical and Non Classical Actions of Calcitriol”, Yale University, Nephrology Grand Rounds, New Haven, CT, USA. May 30 2008.

194. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Chronic Kidney Disease”, Annual Meeting of the Nephrology Society of Puerto Rico, Fajardo, Puerto Rico, USA. July 24 2008.

195. Kaufmann M, Prosser DE, O’Leary B, Byford V, Jones G (2008) 25-OH-D3-24-hydroxylase (CYP24A1): Mutagenesis and Activity Studies Reveal Important Residues Involved in Regioselectivity and Substrate Access. American Society of Bone Mineral Research, Montreal, Canada. Abstract #702, to be presented Sept. 14 2008.

196. Prosser DE, Kaufmann M, Murchie RC, Vong K, Jones G (2008) CYP27A1 Mutations at Phe147 Confer 25-hydroxylase Activity Towards Vitamin D2-type Side-chains. American Society of Bone Mineral Research, Montreal, Canada. Abstract #1951, to be presented September 15 2008.

197. Jones G (2008) **Invited Speaker**: “Expanding Role for Vitamin D in Chronic Kidney Disease: Classical and Non Classical Actions of Calcitriol”, as part of “Dimensions in Dialysis”. Portland, OR, USA. September 25 2008.

198. Jones G (2009) **Invited Speaker.** “What really caused the recent excitement in vitamin D?

Studies of vitamin D-related cytochrome P450s”, Endocrine Scholar Lecture Series, University of Connecticut Health Science Center, April 7 2009.

199. Jones G (2009) **Invited Speaker.** 2009 National Kidney Foundation Spring Symposium. "Expanding Role for Vitamin D in Chronic Kidney Disease" Wednesday, April 23, San Antonio, Texas.

200. Jones G (2009) **Invited Speaker.** 2009 Nevada Dietetic Association. "Vitamin D: Expanding the Role for Vitamin D in Chronic Kidney Disease" Friday, April 24, Reno Nevada.

201. Jones G (2009) **Invited Speaker**: “Vitamin D metabolism and mechanisms of action – an overview” Canada-US Clinical Chemistry Annual Meetings (American Association of Clinical Chemistry and the Canadian Society of Clinical Chemistry). Chicago, USA. July 19-23 2009. **Winner:** **Outstanding Speaker Award by AACC**

202. Kaufmann M, Prosser DE, Jones G (2009) Designer cytochrome P450s: engineering 25-hydroxylase into CYP24A1. Presented at 14th International Vitamin D Workshop, Brugge, Belgium October 4-8 2009.

203. Carter GD, Berry JL, Gunter E, Jones G, Jones J, Makin HLJ, Suif S, Wheeler MJ (2009) Proficiency testing of 25-hydroxyvitamin D (25-OHD) Assays. Presented at 14th International Vitamin D Workshop, Brugge, Belgium October 4-8 2009.

204. Jones G, Byford V, Helvig C, Petkovich M. (2009) Differential disposition of vitamin D2 does not involve CYP24A1. Presented at 14th International Vitamin D Workshop, Brugge, Belgium October 4-8 2009.

205. Invited Delegate: 2009 Bone Health Research Consensus Conference, CIHR Institute of MusculoSkeletal Health and Arthritis, Toronto, ON, Canada, November 9-10, 2009

206. Jones G (2009) **Invited Speaker**: “Current Knowledge of Vitamin D Metabolism and Function” presented at the Indo-US Conference on Latest Scientific Developments in Vitamin D and Health, Hyderabad, India November 13-14, 2009.

207. Jones G (2010) **Invited Speaker:** “Use of vitamin D in the management of CKD/ESRD patients” presented to Heartland Kidney Network (ESRD Network 12) in Kansas City, Missouri, January 14, 2010.

208. Jones G (2010) **Invited Speaker**: “Vitamin D Status: What to measure, How to measure and What does it mean?” Canadian Society for Clinical Chemists, Saskatoon, June 13-16 2010.

209. Jones G (2010) **Invited Speaker:** “Expanding Role for Vitamin D in Health and Disease” Medical Grand Rounds. Holy Name Medical Center, Teaneck, New Jersey. June 29 2010.

210. Jones G (2010) **Invited Speaker**: “Vitamin D Metabolism and Mechanism of Action” in symposium entitled: “Vitamin D Nutritional Status and Risk of Chronic Disease” The 12th Asian-Pacific Congress of Clinical Biochemistry, Seoul, Korea, October 3-7, 2010.

211. Kaufmann M, Prosser D, Mathew T, Jones G (2010) Fifty Mutations of 25-OH-D3-24-hydroxylase (hCYP24A1) provide insights into its regioselectivity and substrate specificity. J Bone Mineral Res **25** (Suppl 1) MO0479, S500. **Winner:** **President’s Poster Award, ASBMR Annual Meeting, Toronto, Canada.**

212. Jones G (2011) **Invited Speaker**: Talk: “2011 IOM Report on Dietary Reference Intakes on Calcium and Vitamin D”, Health Canada, Ottawa, ON, Canada, January 18, 2011.

213. Jones G (2011) **Invited Speaker**: Talk: Café Scientifique on “Vitamin D: Hope or Hype”, Organised by Canadian Institutes of Health Research, Toronto, ON, Canada, February 2, 2011.

214. Jones G (2011) **Invited Debater**: in “The Vitamin D Debate: Facts and Myths”, Organised by Dr Aaron Tubman, Markin Undergraduate Student Research Program in Health and Wellness, University of Calgary, Calgary AB, Canada, February 8, 2011.

215. Jones G (2011) **Invited Speaker**: Grand Rounds: “Recent Advances in Vitamin D & the 2011 IOM Report on Dietary Reference Intakes on Calcium and Vitamin D”, Dept. Family Medicine, Queen’s U, Kingston, ON, Canada, February 15, 2011

216. Jones G (2011) **Invited Speaker**: Talk: “Biochemistry and Metabolism of Vitamin D” in symposium entitled: “Assessing Vitamin D Nutritional Status in Disease”, 21st International Congress of Clinical Chemistry and Laboratory Medicine, Berlin, Germany, May 15-19, 2011.

217. Jones G (2011) **Invited Speaker:** Talk: “New Insights into the role of CYP24A1 in vitamin D metabolism” at 4nd Symposium on Vitamin D Analogs in Cancer Prevention and Therapy" at Schlossberg-Hotel in Homburg, Germany, on May 20-21, 2011. Organizer: Dr Jorg Reichrath, Saarland University Hospital, Germany.

218. Jones G (2011) **Invited Speaker:** Talk: “Use of LC-MS/MS in Clinical and Laboratory Studies of Vitamin D Metabolism” at 4nd Symposium on Mass Spectrometry at University de Sherbrooke, Sherbrooke, Quebec on May 25, 2011. Organizer: Dr Christiane Auray-Blais, University de Sherbrooke, Sherbrooke, Quebec.

219. Jones G (2011) **Invited Speaker**: Talk: Café Scientifique on “Vitamin D: Do we really need more?” Organised by the Canadian Nutrition Society & Canadian Institutes Health Research, Guelph, ON, Canada, June 3, 2011.

220. Jones G (2011) **Invited Speaker:** 2011 Florida Dietetic Association Annual Symposium, July 17-21, 2011. Fort Lauderdale FL, USA. The IOM Recommendations for Vitamin D.

221. Jones G (2011) **Invited Speaker:** on “Vitamin D: Metabolic Defects and Clinical Consequences” at Clinical Mass Spectrometry: Basics and Applications, at Montreal PQ, Canada, September 20, 2011. Organizer: John Vukovic, Waters Canada, Mississauga, ON.

222. Jones G (2011) **Invited Speaker:** on “Advances in Vitamin D Metabolism & Measurement” at Canadian Society Endocrinology & Metabolism Annual Meeting, “Scientific Basis for Medicine” Symposium at Toronto ON Canada on October 27, 2011. Organizer: Dr David Hanley, University of Calgary, Calgary AB.

223. Jones G (2011) **Invited Speaker:** on “Cellular and molecular actions of vitamin D on cancer cells” In: Molecular Mechanisms Of Vitamin D and Cancer at American Institute for Cancer Research Annual Research Conference on Food, Nutrition, Physical Activity and Cancer at Capital Hilton Hotel, Washington DC on November 3-4 2011. Organizers: Drs Steven Clinton and Susan Mayne.

224. Schlingmann KP, Kaufmann M, Weber S, Fehrenbach H, John U, Misselwitz J, Guran T, Hoenderop JG, Bindels RJ, Prosser DE, Jones G, Konrad M. (2011) Mutations in CYP24A1 encoding Vitamin D-24-hydroxylase cause Idiopathic Infantile Hypercalcemia. American Society of Nephrology 44th Annual Meeting, Philadelphia, PA on November 8-13, 2011. Abstract. **Promoted to Oral Program.**

225. Jones G (2012) **Invited Debater**: in “The Second Vitamin D Debate”, Organised by Dr Aaron Tubman, Markin Undergraduate Student Research Program in Health and Wellness, University of Calgary, Calgary AB, Canada, February 3, 2012.

226. Jones G (2012) **Invited Speaker**: on “ Metabolism and Biomarkers of Vitamin D” In 13th Bergmeyer Conference “Vitamin D in Health & Disease” at Garmisch-Partenkirchen, Germany, March 5-7 2012.

227. Gallo S, Rodd C, Vanstone C, Agellon S, Comeau K, Jones G, L’Abbé M, Khamessan A, Sharma A, Weiler H. (2012). Vitamin D dose-response study in breast fed infants from Montréal, Canada: 400 IU/day is sufficient to meet the plasma 25-hydroxyvitamin D threshold of 50 nmol/L but not 75nmol/L by 12 months of age. Experimental Biology, April 21-25, 2012, San Diego, CA, USA.

228. Gallo, S, Comeau K, Vanstone C, Agellon S, Jones G, L’Abbé M, Khamessan A, Sharma A, Rodd C, Weiler H (2012). A daily dosage of 800 IU of vitamin D3 enhances lumbar spine bone mineral accretion from 1 to 3 months of age in breastfed infants, but not thereafter. Canadian Nutritional Society, May 23 – 26, 2012, Vancouver, BC. **Winner Nestle Student Presentation**

229. Gallo S, Rodd C, Vanstone C, Agellon S, Comeau K, Jones G, L’Abbé M, Khamessan A, Sharma A, Weiler H (2012). Supplementation with 400 IU/day of oral vitamin D3 supports ≥50 nmol/L of plasma 25-hydroxy vitamin D but higher intakes are required to reach 75 nmol/L in breast fed infants. Canadian Pediatric Society, June 6-9, London, ON.

230. Gallo S, Comeau K, Vanstone C, Sharma A, Agellon S, L'Abbé M, Khamessan A, Jones G, Weiler H, Rodd C (2012). Redefining normal mineral and calcitropic hormone status in healthy infants. Clinical Chemistry, June 17-20, Quebec City, PQ.

231. Schlingmann KP, Kaufmann M, Prosser DE, Chen A, Jones G, Konrad M. (2012) 24-hydroxylase mutations in idiopathic infantile hypercalcemia. 15th Workshop on Vitamin D, June 20-22, Houston, TX, USA. **Invited Lecture as part of Oral Program**

232. Kaufmann M, Schlingmann KP, Prosser DE, Chen A, Konrad M, Jones G. (2012) In vivo, In silico and in vitro studies of human CYP24A1 identify leucine-148 as a critical residue mutated in idiopathic infantile hypercalcemia. 15th Workshop on Vitamin D, June 20-22, Houston, TX, USA.

233. Kaufmann M, Schlingmann KP, Prosser DE, Chen A, Konrad M, Jones G. (2012) Personalized vitamin D metabolism: single nucleotide polymorphism analysis reveals naturally occurring CYP24A1 variants with altered enzymatic properties. 15th Workshop on Vitamin D, June 20-22, Houston, TX, USA. **Abstract Promoted to Oral Program. Vitamin D Workshop Young Investigator Award Winne**

234. Wicklow B, Gallo S, Majnemer A, Vanstone C, Agellon S, Comeau K, Jones G, L'Abbé M, Khamessan A, Sharma A, Weiler H, Rodd C (2012). Impact of vitamin D on gross motor development: the result of a randomized dose response trial in Canada. ASBMR, October 12-15, Minneapolis, MN, USA. **Winner Poster Presentation.**

235. Walker M, Richardson H, Goss P, Jabs D, Jones G, Kaufmann M, Wactawski-Wende J, Cheung A, Winquist E, Spadafora S, Ellard S, Hey A, Cooke A, Eisen A, Verma S, Lickley L, Tu D, Gelmon K, Meyer RM, King WD (2012) Vitamin D and mammographic density in postmenopausal women: A cohort study nested within the NCIC CTG MAP.3 chemoprevention trial. AACR Frontiers in Cancer Prevention. October 16-19, 2012. Anaheim, CA. Abstract/Poster.

236. Jones G. (2012) Vitamin D Safety: Its Mechanisms and Application. In Symposium: Vitamin D: Minimum, Maximum, Optimum. October 19-20, 2012. Warsaw, Poland. **Invited Speaker**. Abstract published in Standardy Medyczne/Pediatria T. 9:595-604.

237. Jones G. (2012) Clinical Update on Vitamin D. In: 2012 Heart & Stroke Foundation Clinical Update Satellite Symposium. December 7 2012. Toronto, ON. **Invited Speaker**

238. Jones G (2013) Serum vitamin D metabolite assays: past, present, future. In: “Symposium on Vitamin D & Health”, Association for Mass Spectrometry Applications to the Clinical Laboratory Annual Conference, San Diego, CA. February 9-13, 2013. **Invited Speaker**

239. El-Maouche D, Chong WH, Gafni RI, Jones G, Collins MT (2013) Tumor-induced osteomalacia as a model for the study of mineral metabolism. 16th Vitamin D Workshop, San Francisco, CA. June 12-14, 2013. **Oral Program.**

240. Gallagher JC, Kaufmann M, Jones G (2013) Metabolic regulation of serum 25-hydroxyvitamin D by CYP24A1 is an essential step in preventing vitamin D intoxication. Endocrine Society Annual Meeting. June 17 2013, San Francisco, CA. Abstract OR31-1. **Promoted to Oral Program.**

241. Jones G (2013) Vitamin D2 versus Vitamin D3: What difference does a number make? In: The Rank Prize Funds Mini-Symposium on Mechanistic Aspects and Functional Outcomes of Vitamin D. July 8-11 2013, Grasmere, Cumbria, UK. **Invited Speaker**

242. Kaufmann M, Prosser DE, Jones G (2013) The catabolism of vitamin D by CYP24A1. In: The Rank Prize Funds Mini-Symposium on Mechanistic Aspects and Functional Outcomes of Vitamin D. July 8-11 2013, Grasmere, Cumbria, UK. **Winner:** **Young Investigator Award**

243. Kaufmann M, Gallagher JC, Peacock M, Jones G (2013). Ratio of serum 25-OH-D3: 24,25-(OH)2D3 is a novel and sensitive measure of predicting vitamin D deficiency. ASBMR Annual Meeting, Baltimore MD, October 4-7 2013

244. Jones G. (2013) The important role of cytochrome P450s in vitamin D metabolism. Distinguished Lecture Series (July 2013-June 2014), Creighton University, Omaha, NE. Oct 16, 2013. **Invited Speaker**

245. Jones G (2013) Origin and Biological Importance of 3-epi-25-OH-D3. Vitamin D Standardization Program Meeting (NIST/ODS) Gaithersburg, MD, USA Nov 14-15, 2013. **Invited Speaker**

246. Kaufmann M, St-Arnaud R, Rodd C, Jones G (2014) Of knockout mice and men: comparison of vitamin D metabolomes in CYP24A1 knockout mice and patients with loss-of-function mutations of CYP24A1 (IIH) by LC-MS/MS. Association for Mass Spectrometry Applications to the Clinical Laboratory (MSACL) Annual Conference, San Diego, CA. March 2014. Poster Presentation.

247. Jones G, Kaufmann M, Schlingmann K-P, St-Arnaud R, Rodd C (2014) Talk: “The delicate balance of CYP27B1 and CYP24A1 in ensuring optimal 1,25-(OH)2D3 concentrations for human health” at 5th Symposium on Vitamin D Analogs in Cancer Prevention and Therapy" at Krefeld, Germany, on May 2-3, 2014. Organizer: Dr Jorg Reichrath, Saarland University Hospital, Germany. **Invited Speaker**

248. Rousseau-Nepton I, Kaufmann M, Jones G, Sharma AK, Rodd C (2014) The search for CYP24A1 mutations in Canadian Children: An unexpected presentation with nephrocalcinosis despite normal 1,25-(OH)2D and serum calcium. Pediatric Academic Societies Meeting, Vancouver BC. May 2-6 2014. Poster presentation.

249. Kaufmann M, St-Arnaud R, Molin A, Kottler M-L, Jones G. (2014) Of knockout mice and men: use of LC-MS/MS to compare vitamin D metabolic profiles of Cyp27b1-null mice and patients with VDDR–type 1. 17th Vitamin D Workshop, Chicago IL, June 17-20, 2014. **Abstract promoted to the ORAL Program.**

250. Armas LAG, Byford V, Kaufmann M, Jones G. (2014) Raising 25(OH)D levels has no effect on 24,25(OH)2D in dialysis patients. 17th Vitamin D Workshop, Chicago IL, June 17-20, 2014. Poster presentation.

251. El-Maouche D, Kaufmann M, Gafni RI, Jones G, Collins MT (2014) FGF23-Mediated Vitamin D Metabolism in Tumor-induced Osteomalacia. Endocrine Society Annual Meeting, Chicago IL, June 21-24 2014. **Abstract promoted to the ORAL Program.**

252. Jones G (2014) The utility of LC-MS/MS to vitamin D measurement in clinical and research applications.

July 4 2014, Waters Corporation, Wilmslow, UK. **Invited Speaker**.

253. Anderson-Berry A, Jones G, Kaufmann M, Lyden E, Hanson C (2014) Dynamics of 3-epi-25-hydroxyvitamin D3 in premature infants during Neonatal Intensive Care Unit Hospitalization. Annual Meeting of the American Association for Clinical Chemists, Chicago IL, July 27-31, 2014. Abstract B-234. Poster presentation.

254. Hanson C, Jones G, Kaufmann M, Lyden E, Anderson-Berry A (2014) Dynamics of 24,25-dihydroxyvitamin D3 in premature infants during neonatal intensive care unit hospitalization. European Society for Clinical Nutrition and Metabolism, Geneva, Switzerland, Sept 5-9, 2014. **Abstract promoted to the ORAL Program.**

255. Kaufmann M, Jones G, St-Arnaud R, Rodd C, Cooper DP (2014) Of knockout mice and men: comparison of vitamin D metabolomes in CYP24A1-null mice and patients with loss-of-function mutations of CYP24A1 (IIH) by LC-MS/MS. Australasian Association of Clinical Biochemists 52nd Annual Scientific Conference, Adelaide, Australia, October 27-29 2014. Poster presentation.

256. Jones G (2014) LC-MS/MS-based assays offer new insights into vitamin D metabolism in genetic diseases and knockout mouse models, St Justine Hospital, Montreal, PQ, November 20 2014. **Invited Speaker**

257. Djekic-Ivankovic M, Weiler H, Jones G, Kaufmann M, Aleksic-Velickovic V, Mandic L, Glibetic M(2015) Vitamin D status is low in mothers with preeclampsia and their infants: a case control study from Serbia. Canadian National Perinatal Research Meeting, Montebello, PQ, Canada. February 24-27, 2015. Abstract 322.

258. MolinA, Kaufmann M, Tiulpakov A, Jones G, Kottler M-L (2015) *CYP24A1* Molecular Analysis and Simultaneous Assay of multiple vitamin D metabolites by LC-MS/MS in patients with hypercalcemia and suppressed PTH: a cohort study. Endocrine Society 97th Annual Meeting & Expo, March 5-8 2015, San Diego, CA, USA. **Abstract promoted to the ORAL Program**

259. Shah AD, Hsiao E, O’ Donnell B, Salmeen K, Nussbaum R, Krebs M, Baumgartner-Parzer S, Kaufmann M, Jones G, Bikle DD, Mathew AS, Shoback D, Block-Kurbisch I (2015)Recurrent Hypercalcemia in Pregnancy in a Patient with Compound Heterozygous Mutations in CYP24A1. Endocrine Society 97th Annual Meeting & Expo, March 5-8 2015, San Diego, CA, USA. Late Breaking Abstract 22317, Poster, March 5 2015.

260. Jones G (2015) **Invited participant** in Best Brains Exchange on “Vitamin D fortification of the food supply: Are changes to the existing vitamin D policy warranted”. CIHR, Health Canada & Public Health Agency of Canada-sponsored debate, Ottawa ON, March 6 2015.

261. Jones G (2015) LC-MS/MS offers new insights into vitamin D metabolism in humans and knockout animal models. American Chemical Society Annual Meeting. Agricultural and Food Division Symposium on “Vitamin D: past and future for animals and humans” Denver, CO, USA, March 22-26, 2015**. Invited Speaker**

262. Djekic-Ivankovic M, Weiler H, Jones G, Kaufmann M, Aleksic-Velickovic V, Mandic L, Glibetic M(2015) Vitamin D status is low in mothers with preeclampsia and their infants: a case control study from Serbia. Experimental Biology Annual Meeting, Boston MA, USA. March 28-April 1, 2015. Abstract 4575, Poster presentation March 29 2015.

263. Djekic-Ivankovic M, Jones G, Kaufmann M, Weiler H (2015) Plasma 3-epi-25-hydroxyvitamin D3 in very low birth weight preterm infants in Canada during the first five weeks after birth. Experimental Biology Annual Meeting, Boston MA, USA. March 28-April 1, 2015. Abstract 6711, Poster presentation March 31 2015.

264. Jones G (2015) Vitamin D Metabolic Profiling using Liquid Chromatography-Tandem Mass Spectrometry

(LC-MS/MS). 18th Vitamin D Workshop, Delft, Netherlands April 21-24. **Invited Speaker**

265. Carter GD, Jones JC, Shannon J, Walker E, Jones G, Kaufmann M, Sempos CT, Wise SA, Sander L, Burdette CQ, CamaraJE, TaiS. (2015) 25-Hydroxyvitamin D Assays: Potential interference from other circulating Vitamin D Metabolites. 18th Vitamin D Workshop, Delft, Netherlands April 21-24.

266. Kaufmann M, Lee S-M, Pike JW, Jones G. Changes in the Vitamin D Metabolome in a VDR-null mouse model before and after rescue with a high Ca-high lactose diet. 18th Vitamin D Workshop, Delft, Netherlands April 21-24.

267. Hanson C, Anderson-Berry A, Lyden E, Kaufmann M, Jones G. Maternal-fetal dynamics of vitamin D metabolites. 18th Vitamin D Workshop, Delft, Netherlands April 21-24.

268. Kaufmann M, Molin A, Tiulpakov A, Jones G, Kottler M-L (2015) Simultaneous Assay of multiple vitamin D metabolites by LC-MS/MS for the screening of patients with hypercalcemia and *CYP24A1* mutations. A cohort study. 18th Vitamin D Workshop, Delft, Netherlands April 21-24. **Abstract promoted to the ORAL Program**

269. Jones G (2015) 3-epi-25-OH-D3: Its Origins and Biological Significance. Vitamin D Standardization Program. Cambridge University, Cambridge UK, June 29-30, 2015. **Invited Speaker**

270. Schlingmann KP, Ruminska J, Kaufmann M, Dursun I, Kranz B, Pronicka E, Ciara E, Akcay T, Güran T, BulusD, Cornelissen E, Gawlik A, Sikora P, Patzer L, Galiano M,Boyadzhiev V, Dumic M, Vivante A, Anikster Y, Kleta R, Levtchenko E, Bindels RJ, Rust S, Stoll M, Forster IC, HernandoN, Jones G, Wagner CA, Konrad M (2015) Recessive Mutations in SLC-34 (Na-Pi-IIa) cause Idiopathic Infantile Hypercalcemia, ESPN 48th Annual Meeting. Brussels, Belgium. September 3-5, 2015

271. Kaufmann M, Molloy BJ, Sheftel J, Cooper DP, Jones G (2015) Quantification of serum 1,25-(OH)2D3 by UPLC-MS/MS: Comparison of methods involving liquid-liquid extraction, immuno-extraction and chemical derivatization. MSACL 2015 EU, Salzburg, Austria, September 8-11 2015.

272. Jones G (2015) New insights into vitamin D metabolism revealed by liquid chromatography tandem mass spectrometry. Penn State University, Bortree Seminar Series, September 23 2015. **Invited speaker**.

273. Carlson AH, Kaufmann M, St Arnaud R, Jones G, Pike JW (2015) Mouse and Human Bacterial Artificial Chromosomes Encoding the *CYP24A1* Loci Rescue the Ability of *Cyp24a1* Null Mice to Catabolize 25-Hydroxyvitamin D3 to 24,25-Dihydroxyvitamin D3 and 25-Hydroxyvitamin D3-26,23-Lactone.

ASBMR Annual Meeting, Seattle, WA. October 9-12, 2015

274. Jones G (2015) Biomarkers of vitamin D-current state of knowledge. Vitamin D: Minimum, maximum, optimum. Warsaw, Poland, October 16-17, 2015. **Invited speaker.**

275. Ting S, El-Damanawi R, Tomkins R, Lim K, Kaufmann M, Jones G, Zehnder D, Hiemstra TF (2015) Vitamin Metabolism is Incompletely Restored after Kidney Transplantation, ASN Annual Meeting, San Diego, CA, November 3-8, 2015, Abstract not accepted.

276. CarterGD, Berry J, DurazoArvizu R, Gunter E, Jones G,Jones J, Makin HLJ, Pattni P, Phinney KW, Sempos CT, Williams EL. (2016) DEQAS: Quality assessment of vitamin D metabolite assays used by clinical and research laboratories. 19th Workshop on Vitamin D, Boston MA March 28-31, 2016.

277. Kaufmann M, Morse N, Molin A, Kottler M-L, Schlingmann K-P, Jones G (2016). Improved LC-MS/MS Assay For 24,25-(OH)2D3 explains the residual CYP24A1 Enzyme Activity Observed In Patients With Idiopathic Infantile Hypercalcemia (IIH). 19th Workshop on Vitamin D, Boston MA March 28-31, 2016. Poster.

278. Molin A, Feillet F, Demers N, Wiedemann A, Brennan S, Kaufmann M, Jones G, Kottler M-L (2016) Two French families with Vitamin D Dependency Rickets Type 1b harbor homozygous recessive expression of CYP2R1 mutations L99P and G42\_I46del insR. 19th Workshop on Vitamin D, Boston MA March 28-31, 2016.

279. Jones G (2016) MS Society of Canada’s Vitamin D and Multiple Sclerosis Expert Panel Meeting, Toronto, March 4 2016. **Invited participant**

280. Jones G, Schlingmann K-P (2016) New insights into the causes, screening tools and potential treatments for idiopathic infantile hypercalcemia. E-RARE Monitoring Meeting, Barcelona, Spain, March 8, 2016. **Invited speaker**

281. Jones G (2016) “Vitamin D update” in Management strategies for secondary hyperparathyroidism in CKD: vitamin D supplementation. National Kidney Foundation 2016 Spring Clinical Meeting, Boston, April 28 2016. **Invited speaker**

282. Jones G (2016) CYP24A1 mutations and human disease. In Symposium 14: Hot topics on vitamin D, 18th European Congress of Endocrinology, Munich, Germany, May 28-31, 2016. **Invited speaker.**

283. Jones G (2016) What can we learn from measuring 24,25-(OH)2D3? In Symposium: Vitamin D: Analytical and Clinical Stories. The Association for Clinical Biochemistry and Laboratory Medicine, Imperial College, London July 7 2016. **Invited speaker.**

284. Jones G (2016) Mutations of the vitamin D catabolic cytochrome P450, CYP24A1: Kidney stones in knockout mice and men. Ottawa Hospital Research Institute, July 11 2016. **Invited Speaker.**

285. Kaufmann M, Arabian A, Conrad P, Vig M, Berezin L, St-Arnaud R, Jones G (2017) Opposumouse (A326G), Hypercalcimouse (R396W) and Anabolimouse (V391L): Insights into in vivo metabolism of vitamin D using knock-in models of CYP24A1 variants. 20th Workshop on Vitamin D, Orlando FL. March 27-31, 2017. **Abstract promoted to the ORAL Program.**

286.Meyer MB, Benkusky NA, Lee SM, Onai M, Kaufmann M, Jones G, Pike JW (2017) Identification of the genomic & homeostatic circuitry controlling CYP27B1 in vivo. 20th Workshop on Vitamin D, Orlando FL. March 27-31, 2017. **Abstract promoted to the ORAL Program**

287. Pike JW, Carlson A, Benkusky NA, Lee SM, Jones G, Kaufmann M and Meyer MB (2017) Differential enhancer-mediated regulation of *CYP24A1* in the kidney and non-renal target cells in vivo. 20th Workshop on Vitamin D, Orlando FL. March 27-31, 2017. **Abstract promoted to the ORAL Program**

288. Jones G (2017) The discovery and synthesis of the nutritional factor, vitamin D. In the Symposium: “Vitamin D Deficiency: New Perspectives Under Past Light” at the Annual Meeting of the International Society of Paleopathology, New Orleans, LA, April 19 2017. **Invited Speaker.**

289. Jones G (2017) Workshop on “The Role of Vitamin D in Stage 3-4 CKD”. Atlanta, GA May 18-19 2017. **Invited Participant**.

290. Jones G (2017) Assay of other vitamin D metabolites. In: 1st International Conference on Controversies in Vitamin D. Pisa, Italy. Organisers: Bilezikian J, Giustina A. June 14-16 2017. **Invited Speaker.**

291. Jones G (2017) When prolonged vitamin D intake confers a risk for health. In: Third International Conference “Vitamin D - Minimum, Maximum, Optimum” EVIDAS 2017. Warsaw, Poland. September 22-23 2017. **Invited Speaker**.

292. Jones G (2017) Ratio of 25(OH)D to 24,25(OH)2D3 and its use in clinical medicine. In: Vitamin D Standardization Program (VDSP) The Road Ahead. Rockville, Maryland, November 28-30 2017.

**Invited Speaker**.

293. Jones G (2017) 3-Epi-25-OH-D3: Origins and Biological Importance. In: Vitamin D Standardization Program (VDSP) The Road Ahead. Rockville, Maryland, November 28-30 2017. **Invited Speaker**.

294. Razaghi M,Vanstone CA, Agellon S, Kimmins S, Wei S, McNally D, Rauch F, Jones G, Weiler HA. (2018) Low newborn vitamin D status is associated with lower lean mass at 6 mo of age despite infant vitamin D supplementation. Canadian Nutrition Soc. Annual Conf., Halifax, NS May 3-5 2018. Abstract submitted.

295. Sotunde O, Vanstone CA,LaveryP, Farahnak Z, Razaghi M, Gharibeh N, Shero N, Albuayjan N, Patel S, Wei S, Kaufmann M, Jones G, Weiler H. (2018) Rise in serum 3-epi-25-hydroxyvitamin D3 is associated with weight velocity in early infancy. Amer Soc Nutrition, Boston MA. June 9-12, 2018. Abstract submitted.

296. Jones G (2018) Genetic Disorders of Vitamin D Metabolism. In: “Symposium on Vitamin D” organized by DeLuca HF. Amer Soc Nutrition, Boston MA. June12, 2018. **Invited Speaker**.

297. Jones G (2018) Threshold for Defining Vitamin D Excess. In: 2nd International Conference on Controversies in Vitamin D. Monteriggioni, Italy. Organisers: Bilezikian J, Giustina A. September 11-14 2018. **Invited Speaker.**